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Summary  
Alzheimer’s disease (AD) is the most frequent form of dementia among the elderly 
affecting dozens of million people worldwide. Post-mortem, the disease is characterized by 
two main neuropathological hallmarks: extracellular amyloid plaques and intracellular 
neurofibrillary tangles (NFTs). Amyloid plaques are composed of the amyloid-beta (Aβ) 
protein, derived from its amyloid precursor protein (APP). NFTs are formed from paired 
helical filaments composed of hyperphosphorylated tau, a microtubule-associated-protein. 
Besides these well-characterized features, a growing body of evidence supports mitochondrial 
dysfunctions as part of the spectrum of chronic oxidative stress occurring in AD. This energy 
deficit may contribute finally to synaptic abnormality and neuronal degeneration observed in 
selected brain areas of AD patients. Nevertheless, the specific mechanisms leading to 
mitochondrial failure as well as the role of Aβ or/and tau within this process are only partly 
understood.  
 
The purpose of the thesis was therefore to elucidate the role of mitochondria in the 
pathogenesis of AD. Specifically the thesis was designed to determine (1) the synergistic 
effects of Aβ-tau interplay, (2) the impact of soluble Aβ forms and (3) effects of Ginkgo 
biloba extract (GBE) on mitochondria in several models of AD. 
 
(1) While many studies reported effects of amyloid plaques on energy metabolism, the 
role of tau pathology was until recently unknown. In a previous study, our group has been the 
first to show that tau was also able to induce mitochondrial dysfunction and raise reactive 
oxygen species (ROS) levels in brains of P301L mutant tau transgenic pR5 mice (pR5). 
Moreover, we found an increased mitochondrial vulnerability of pR5 cortical cells towards 
Aβ in vitro. Based on these findings, we hypothesized that Aβ and tau might share toxicity at 
the mitochondrial level. To reveal proof in vivo, we investigated the brains of wild-type 
control mice and three transgenic mouse models. Transgenic pR5 mice express P301L mutant 
tau found in the frontotemporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17), a dementia related to AD. These mice model the tangle pathology of AD but lack 
Aβ plaques. Furthermore, they show a hippocampus- and amygdala-dependent behavioural 
impairment related to AD. APP152 double-transgenic mice co-express the N141I mutant form 
of PS2 together with the APPSwe mutant found in familial cases of AD (FAD). These mice 
model the Aβ plaques pathology, but fail to form NFTs. In addition, the mice display age-
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related cognitive deficits associated with discrete brain Aβ deposition and inflammation. 
Finally, we crossed the two strains to generate tripleAD mice. In addition to be a robust model 
mimicing both plaques and tangles, this new transgenic line presents both amyloidosis and 
NFTs formation in an age-dependent manner. The progression of biochemical changes and 
histopathological features in the mice is reminiscent of the course of AD pathogenesis. The 
mice develop behavioral deficits before detection of protein aggregates correlating with the 
early mitochondrial dysfunction hypothesis proposed in AD. We applied the optimized 
quantitative mass-tag labelling proteomic technique, iTRAQ and nanoLC-ESI MS/MS mass 
spectrometry, followed by sophisticated high-resolution assays for metabolic and energetic 
functions. We demonstrated massive deregulation of 24 proteins of which one third were 
mitochondrial proteins mainly related to complexes I and IV of the mitochondrial respiratory 
system from the four strains of mice. Our functional analysis validated the proteomic 
approach by confirming the strongest defects of the respiratory capacity mainly at complexes 
I, IV and V in tripleAD mice. Taken together, we demonstrated for the first time stringent 
mitochondrial respiratory capacity dysfunction and a failure to restore the energy metabolism 
in presence of both Aβ and tau.  
 
(2) However, how these lesions and their proteinaceous components impair 
mitochondrial functions and ultimately lead to neuronal cell loss are unresolved so far. 
Intriguingly, some recent studies suggest that oligomeric Aβ species may be the main culprit, 
rather than fibrillar. This idea highlights the critical role of mitochondrial abnormalities in the 
biochemical pathway by which intracellular Aβ can lead to neuronal dysfunction in AD. To 
test this experimental paradigm, we examined in a second study the specific effects of soluble 
Aβ on mitochondrial function under physiological conditions. To this end, human 
neuroblastoma cells (SH-SY5Y) were stably transfected with cDNAs containing either a 
vector alone (control cells) or the entire coding region of human wild-type APP (APP695). 
APP cells led to a significantly increased Aβ secretion compared to control cells and mimiced 
relevant conditions for AD patients as Aβ levels were within a picomolar range. We 
established a novel high-resolution respiratory protocol to perform whole cell recording of 
total cellular respiration and mitochondrial metabolic states. To ripen our analyses, individual 
activity of mitochondrial respiratory enzymes (complex I to IV) and ATP levels were 
measured. We concluded that chronic exposure to soluble Aβ results (i) in serious impairment 
of mitochondrial respiratory machinery due to activity changes of complexes III and IV 
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leading finally to (ii) a drop of ATP synthesis. This energy metabolism deficit may in turn 
accelerate/lead to cell death commonly observed in AD.  
 
(3) Finally, we resumed the previous work by investigating the potential protective 
effect of standardized GBE (LI 1370) on Aβ-induced mitochondrial failure. Mainly, the 
antioxidant properties of GBE have been proposed as dietary strategies for many years in age-
related cognitive disorders including AD. We showed for the first time that under 
physiological conditions GBE improves metabolic energy pathways by increasing the 
coupling state of mitochondria per se, but with specific benefit in APP cells exhibiting Aβ-
induced mitochondrial failure. GBE effect on OXPHOS was even preserved in mitochondria 
after isolation from treated cells. The GBE-induced amelioration of oxygen consumption most 
likely arose from the modulation and respective normalization of the activity of mitochondrial 
complexes I, III and IV that are markedly disturbed in APP cells finally yielding a rise in ATP 
levels. Of note, these functional data were paralleled by an up-regulation of mitochondrial 
DNA in GBE-treated cells. 
 
In summary, the present thesis took aim to highlight the key role of mitochondria in 
AD pathogenesis and the close inter-relationship of this organelle with the two main 
pathological features of the disease. First, we demonstrated main defects of mitochondrial 
respiratory capacity and the failure to restore energy homeostasis in mice with plaques and 
tangles. Although, a molecular link between Aβ and tau is still missing, these in vivo results 
consolidate the idea that a synergistic effect of tau and Aβ augments the pathological 
deterioration of mitochondria in AD by driving a vicious cycle. Secondly, we proved toxicity 
of soluble Aβ forms, recently defined as the toxic correlate within the Aβ cascade, on the 
mitochondrial function of vital cells. Finally, the critical role of mitochondria in early 
pathogenesis of AD may make them into a preferential target for treatment strategies such as 
antioxidants. Our work confirmed this idea and clearly showed stabilization and restoration of 
energy metabolism in APP cells treated with GBE. In view of the increasing interest in 
mitochondrial protection as treatment strategy in dementia, our findings of substantial 
protection of mitochondria by GBE against Aβ-induced dysfunction deserves further 
attention. 
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1. Introduction 
 1.1. Alzheimer’s disease 
In 1907, the German psychiatrist and neuropathologist Alois Alzheimer published a 
report concerning “an unusual illness of the cerebral cortex”[11-13] that Emil Kraepelin 
subsequently named after him[14]. He described the case of a 51-year-old woman, Auguste D., 
who initially developed a delusional disorder followed by a rapid loss of short term memory. 
Post-mortem examination of her brain, using a silver staining method, revealed a cortical 
atrophy without evidence for focal degeneration and the presence of two histopathological 
modifications. 
 
1.1.1. Clinical symptoms          
One century later, Alzheimer’s disease (AD) has become the most common age-
related neurodegenerative disorder affecting around 27 million people worldwide[15]. As the 
prototype of cortical dementias, AD develops prominent cognitive defects. The clinical 
scenario begins by episodic memory deficits with preserved alertness and motor function. The 
syndrome of mild cognitive impairment (MCI), characterized by a subtle decrease in short-
term declarative memory with otherwise normal cognition, is often a harbinger of AD. Over 
time, gradual erosion of other cognitive abilities appear and lead to profound language, 
abstraction and orientation impairments[16]. Besides the cognitive deterioration, patients 
display dramatic neuropsychiatric symptoms as mood disturbances, delusions and 
hallucinations, personality changes and disorders of behavior (aggressiveness, depression, 
circadian disturbances)[17]. In contrast with cognitive symptomatology, the non-cognitive 
defects do not show a progressive course[2]. Patients who usually survive 7 to 10 years (range 
2-20 years) after the onset of symptoms[18] typically died from medical complications 
(bronchitis or pneumonia)[19]. Despite manifest progresses in clinical diagnosis, brain biopsy 
is still required to confirm AD[20]. Characteristically, severe neuropathological changes occur 
in selective cognitive domains, particularly those related to memory and emotional behavioral 
such as the hippocampus, association cortices and subcortical structures including the 
amygdala and nucleus basalis of Meynert[21].  
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1.1.2. Neuropathological phenotype  
The key neuropathological features of AD are abundant amounts of extracellular 
plaques composed of the amyloid-beta (Aβ) protein and intracellular neurofibrillary lesions 
formed of hyperphosphorylated tau, a microtubule-associated protein. Besides these 
histopathological characteristics described for the first time by Alzheimer that are still 
considered as the two main pathognomic features of AD, numerous other structural and 
functional alterations like energy dysfunction, oxidative stress[4, 22] and inflammatory 
responses[23-26] are associated with AD. The combined consequences of all the pathological 
changes lead to massive neuronal demise and synapse loss at specific brain regions involved 
in learning and memory[6] (Figure 1). Neurons that use glutamate or acetylcholine as 
neurotransmitters appear to be particularly affected, but cells that produce serotonin and 
norepinephrine are also damaged. At the time of death, the brain of a patient with AD may 
weigh one-third less than the brain of an age-matched, non-demented individual[27].  
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Figure 1. Histopathological modifications during progression of Alzheimer’s disease. (A) Schematic 
representation of a normal healthy synapse. (B) At very early stages of Alzheimer’s disease (AD), abnormal 
hyperphosphorylated tau protein and amyloid-beta peptide (Aβ) oligomers start to disturb the synaptic
homeostasis including energy metabolism and molecular pathways (yellow box). (C) At late stages of the 
disease, neurofibrillary tangles and Aβ fibrils / plaques combined with glial changes and inflammation 
exacerbate these deficits finally leading to synaptic failure and neurodegeneration (from Rhein et Eckert, 
2007[4]). 
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1.1.3. Epidemiology and genetics  
AD is a devastating neurodegenerative disorder. As proof, the statistics attributable to 
the disease are vertiginous. AD is the most common cause of dementia comprising 50-70% of 
all cases[7] and affecting nearly 2% of the population in industrialized countries. Age is the 
greatest known risk factor for AD with an incidence of 25–50% in people aged 85 or older[28]. 
The number of patients is expected to increase threefold within the next 50 years[29] as a result 
of demographic changes and rising life expectancy. In 2050, 50% of people worldwide aged 
85 or older may be affected by the disease if no suitable cure is found[30]. Today, AD is the 
fifth leading cause of death in people aged 65 and older, and most patients eventually need 
nursing home care. 
 
 
While the complete etiological picture of AD remains still fragmentary, it is now 
widely accepted that, in addition to environmental conditions, genes play an essential role in 
predisposing to an early onset and/or modifying the progress of the disease. Twin studies 
support the notion that 70–80% of the risk to develop AD is determined by genetic factors[31]. 
However, genetically, AD is a complex and heterogeneous disease involving mutations and 
polymorphisms in multiple genes on several chromosomes and showing an age-related 
dichotomy. AD is therefore classified into two forms: the late sporadic AD (SAD) and the 
early familial AD (FAD). Importantly, other than the age of onset, the clinical and 
histopathological features cannot discriminate between the two AD forms. 
 
SAD represents the vast majority of cases whose aging itself is the unique important 
risk factor known[32]. Until today, only the apolipoprotein E (APOE) gene located on 
chromosome 19q13.2 has been confirmed unanimously as a risk gene[33, 34]. Its ε4 allele 
increases the susceptibility to SAD whereas its ε2 allele confers protection against the late-
onset of AD[35]. However, inheriting the ε4 allele of APOE is not sufficient to cause the 
disease. Numerous genetic factors of only minor to moderate effect are likely to play 
simultaneous and possibly interdependent roles, making the identification of novel genes 
gruelling. Nevertheless, the recent development of powerful and sophisticated genotyping 
approaches, like the high-density genome-wide association, may be promising tools to 
chararacterize other SAD susceptibility genes. For instance, the overexpression of the growth 
factor receptor-bound protein associated binding-protein 2 (GAB2) gene, encoding a 
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scaffolding protein involved in multiple signalling pathways, may modify SAD risk in APOE 
ε4 carriers[36]. Moreover, mutations of the very low-density lipoprotein receptor (VLDL-R) 
gene on chromosome 9, the insulin-degrading enzyme (IDE) gene on chromosome 10 as well 
as the α2-macroglobulin (A2M) gene and the Low-density lipid receptor-related protein 
(LRP) gene on chromosome 12 are also proposed as potential candidates for SAD genes[37, 38]. 
 
Besides cases arising sporadically, epidemiological studies indicate that about 30% of 
AD patients have a family history of disease in which at least one first-degree relative is 
affected, but only few of them have a clear autosomal dominant inheritance[39]. In point of 
fact, FAD which starts before 60 accounts for less than 1% of the total number of AD cases. 
Since the nineties, more than 20 pathogenic mutations in amyloid precursor protein (APP) 
gene[40-43] map to chromosome 21q21.3-21q22.05 have been identified and estimated for up to 
5% of FAD (e.g. V717I ‘London’, K670D/M671L ‘Swedish or APPSwe’) (Figure 2). Some 
APP mutations cause also cerebral amyloid angiopathy (CAA) described as amyloid deposits 
in walls of blood vessels of the central nervous system[44, 45]. CAA is present in over 80% of 
AD cases. Most FAD cases are caused by mutations in two other genes, presenelin 1 (PSEN1) 
located on chromosome 14q24.3 and presenelin 2 (PSEN2) on chromosome 1q31-q42[46, 47], 
of which over 130 have been identified. Remarkably, all of FAD mutations identified in these 
three genes result in the overproduction of Aβ, further providing evidence that Aβ plays a 
crucial role in the pathogenesis of the disease. In AD, no mutation has been identified in the 
gene encoding tau, MAPT. However, more than 30 exonic and intronic mutations in MAPT, 
map to chromosome 17q21.1, have been found in a familial dementia related to AD, the 
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17)[48-50]. The 
majority of these mutations (e.g. G272V, V337M, R406W and P301L) are located in the 
microtubule binding repeat region or close to it and reduce tau ability to promote microtubule 
assembly[51] and lead to tau aggregation into NFTs (Figure 2). Gallyas silver impregnation 
techniques are frequently employed to visualize NFTs in both AD and FTDP-17 brains[52]. 
Interestingly, in contrast to AD, there are almost no senile plaques in FTDP-17, suggesting 
that mutant tau is sufficiently potent to induce tau aggregation and does not need any 
enhancer such as Aβ. Importantly, these findings established that dysfunction of tau in itself 
can cause neurodegeneration and lead to dementia. 
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1.1.4. Cleavage pathway of APP and Aβ deposits  
The first histopathological hallmark, described by Alzheimer as a “peculiar substance” 
occurs as extracellular deposits. In the mid-1980s, it was discovered that the deposits consist 
of aggregates of small 40–42 amino acid polypeptide β-amyloid (Aβ40 and Aβ42) termed     
Aβ[53, 54]. Aβ deposits can either or not be surrounded by dystrophic neuritis, activated 
microglia and reactive astrocytes. The first case characterizes neuritic or senile plaques while 
the second refers to as “diffuse” plaques. Importantly, amyloid plaques do not occur simply in 
these two extreme forms (diffuse and neuritic) but rather as a continuum associated with 
varying degrees of surrounding neuritic and glial alterations. In addition, assault of Aβ 
peptide on endothelial cell walls may form lesions in case of excessive deposits and cause 
CAA which can present as intracranial haemorrhage[55]. Although, several studies have staged 
       
 
Figure 2. APP mutations associated with early-onset Alzheimer’s disease (FAD) and tau mutations in 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). (A) Most APP mutations 
are clustered in the close vicinity of secretase-cleavage sites, indicated by scissors, thereby influencing APP 
processing and are named after the nationality or location of the first family in which that specific mutation was 
demonstrated. The Aβ sequence is indicated in red (from Van Dam and De Deyn, 2006[2]). (B) Schematic 
diagram of the longest tau isoform (441 amino acids) with mutations in the coding region. Twenty missense 
mutations, two deletion mutations and three silent mutations are shown (adapted from Goedert and Jakes, 
2005[10] ). 
A B 
Exon 2 
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the progression of Aβ deposits in brain of AD patients, these studies findings are still a 
controversial issue[9, 56-58]. It is widely accepted that the distribution pattern and packing 
density of Aβ deposits turn out to be of limited significance for differentiation of 
neuropathological stages. The dispersion of neuritic plaques varied largely not only within 
architectonic units but also from one individual to another. 
 
APP is a cellular ubiquitous glycoprotein whose amount varied according to the 
developmental and physiological state of cells. Although incompletely understood, increasing 
evidence suggests a role of APP in regulating neuronal survival, neurite outgrowth, synaptic 
plasticity and cell adhesion[59]. Structurally, APP is a single transmembrane receptor like 
protein, from 695 to 770 amino acids, with a large extracellular glycosylated amino-terminus 
(Nt), a shorter cytoplasmic carboxy-terminus (Ct) and is partly embedded up to its Aβ 
fragment in the plasma membrane, the lumenal side of endoplasmic reticulum, Golgi and 
mitochondrial membranes[60-62] (Figure 3). APP can be cleaved by associated proteases 
termed α-, β- and γ-secretases. Three enzymes, all belonging to the ADAM family (a 
disintegrin- and metalloproteinase-family enzyme): ADAM9, ADAM10 and ADAM17 (or 
tumour necrosis factor converting enzyme)[63] have been identified with α-secretase activity. 
The activity of β-secretase has been attributed to a single protein, BACE 1[64], whereas γ-
secretase activity depends on four components, presenilin, nicastrin, anterior pharynx-
defective 1 (APH1) and presenilin enhancer 2 (PEN-2)[65]. In the prevalent non-
amyloidogenic pathway, cleavage of APP by α-secretase releases αAPPs and leaves an 83-
amino-acid Ct APP fragment (C83). Following cleavage of C83 by γ-secretase produces a 
short fragment termed p3[66] and the Aβ intracellular cytoplasmic domain (AICD)[6]. 
Importantly, cleavage by α-secretase occurs within the Aβ region, thereby precluding 
formation of Aβ[7]. The alternative amyloidogenic processing involves sequential cleavages 
by BACE 1 and γ-secretase and leads to Aβ and AICD generation[6]. The initial proteolysis is 
mediated by β-secretase at a position located 99 amino acids from the Ct. This cut results in 
the release of βAPPs into the extracellular space, and leaves the 99-amino-acid Ct stub (C99) 
within the membrane, with the newly generated Nt corresponding to the first amino acid of 
Aβ. Subsequent cleavage of this fragment (between residues 38 and 43) by γ-secretase 
dictates the length of Aβ peptide (Figure 3). In healthy individuals, most of the full-length Aβ 
peptide normally produced by brain cells throughout life is Aβ40, whereas a small proportion 
(approximately 10%) is Aβ42[53, 54]. In AD, both Aβ variants may form oligomeric aggregates 
that are thought to represent the “primary toxic correlate” and eventually deposits as plaques. 
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Aβ42 is more hydrophobic[67] and consequently more prone to fibril formation and neurotoxity 
than the shorter form[68]. Recent evidence even suggests that Aβ40 may prevent Aβ42 from 
aggregating and forming plaques[69]. Aβ42 is the predominant compound in neuritic plaques[70] 
which are therefore mainly built of insoluble amyloid fibrils up. On the opposite, diffuse 
plaques exist mostly in a nonfibrillar form termed “preamyloid”[71, 72].  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N-term C-term
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
TM
non-amyloidogenic pathway proteolytic pathway
(α-secretase) (β-secretase)
β-secretase α-secretase γ-secretase
β-APPs C99
Aβ40
Aβ42
Aβ
α-APPs C83
p3
Aβ plaques
AICD AICD
extracellular intracellular
non-toxic and clear
from the brain
non-demented
and healthy
amyloid precursor protein (APP)
toxic, accumulate in the cellular compartments
and impair cellular functions, including 
mitochondrial dysfunction, synaptic dysfunction
and hyperphosphorylation of tau
dementia and Alzheimer’s disease
 
 
 
Figure 3. APP and its metabolites. The amyloid-β (Aβ) peptide is derived by proteolytic cleavage from the 
amyloid precursor protein (APP). The most frequent enzymatic cleavage is mediated by α-secretase (purple 
arrow), occuring within the Aβ domain, thereby preventing the generation and release of Aβ. Two fragments are 
released, the larger ectodomain (α-APPs) and the smaller carboxy-terminal fragment (C83). Furthermore, C83 
can also undergo an additional cleavage mediated by γ-secretase (blue arrow) to generate p3 and the Aβ 
intracellular cytoplasmic domain (AICD). APP molecules that are not cleaved by the non-amyloidogenic 
pathway become a substrate for β-secretase (green arrow) releasing an ectodomain (β-APPs), and retaining the 
last 99 amino acids of APP (C99) within the membrane. C99 is subsequently cleaved by γ-secretase complex 
(blue arrows), which predominantly produces Aβ1–40, and the more amyloidogenic Aβ1–42 at a ratio of 10:1, as 
well as AICD. 
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1.1.5. Phosphorylation of tau and development of neurofibrillary lesions 
Alzheimer observed in the brain of his original patient a second lesion which co-
occurs with Aβ plaques. But unlike Aβ deposits, these protein aggregates were present 
intraneuronally. In the late 1980s, it was discovered that they are composed of abnormally 
hyperphosphorylated microtubule-associated protein tau[73-75]. 
 
Structurally, human tau proteins consist of a heterogeneous mixture of six isoforms 
ranging from 50 to 70kDa and from 352 to 441 residues[76, 77] (Figure 4A). Tau is very 
hydrophilic and adopts natively an unfolded conformation with rare α-helices and                  
β-sheets[78-80]. It contains a Nt acidic region, a middle basic and proline-rich region, and a Ct 
region with three (3R) or four (4R) microtubule binding repeats[81]. The isoforms derived by 
alternative mRNA splicing[82, 83] from a single gene (16 exons) located on chromosome 17. 
They differ in the presence of 3R or 4R constituted of 31 or 32 amino acids encoded by the 
exon 10 (E10), and the presence of one, two or none Nt inserts of 29 amino-acids (N1/N2) 
encoded by the exon 2 and/or 3 (E2/E3). In general, tau with 4R binds to microtubules more 
tightly than tau presenting 3R[84-86]. Tau is predominantly located in neuronal axons and if it 
could be partially enriched in soma, it is in contrast almost totally absent in dendrites[87, 88]. 
Small amounts of tau are also found in oligodendrocytes and astrocytes[89, 90]. Its main 
biological function is to promote the assembly and stabilization of the microtubular 
network[91, 92], essential for normal axonal transport[93]. In addition, tau may be a 
communication interface between mitochondria[94], cytoskeletal elements[95-97], and plasma 
membrane[98, 99] and play a role in signal transduction interacting with many phosphatases and 
kinases[100-103]. Tau is termed a phosphoprotein owing to its large number of potential 
phosphorylation sites, almost 20% of the molecule[104]. This distinctiveness is due to the high 
frequency of serine and threonine residues and its open structure affording access to many 
kinases[105]. Importantly, the majority of phosphorylation sites is clustered in flanking regions 
of the microtubule binding domain[76]. As a consequence, phosphorylation is a key 
mechanism that regulates tau’s interaction with tubulin and other proteins[106, 107]. 
 
Under pathological conditions as in AD, tau exhibits abnormally 
hyperphosphorylation which means that it is phosphorylated to a higher degree at 
physiological sites, and at additional “pathological” sites[93] (Figure 4B). The phosphorylation 
level of tau in AD brains was shown to be three- to four-fold higher than that in normal 
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human brains[108]. Recent data highlighted several kinases in the phosphorylating process like 
glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5 (cdk5), extracellular 
signal-regulated kinase 2 (ERK2), protein kinase A and C, calcium-calmodulin dependent 
protein kinase II (CaMKII), and mitogen-associated protein affinity-regulating kinases 
(MARK)[109, 110]. In addition, tau undergoes conformational changes which likely assist in the 
differential phosphorylation[111]. The phosphorylation especially of microtubule-binding 
repeat domains[112, 113] combined with conformational changes result in the detachment of tau 
from microtubules and its aggregation in the form of two cytosolic pro-fibrillar structures[114]: 
the paired helical filaments (PHFs) and the straight filaments. The presence of additional 
proteins like microtubule-associated protein 1 and 2 (MAP1, MAP2) and Pin1[99] to the six tau 
isoforms widely-accepted as main compounds of pro-filaments is still controversial[73, 115]. 
PHFs are composed of two strands of filaments twisted one around another with a periodicity 
of 80nm and a width varying from 8 to 20nm[116]. Straight filaments lack this helical 
periodicity[117]. Although, the structural basis explaining differences between a twisted and a 
straight filament remains unresolved, some authors propose a role of the β-sheet secondary 
structure forming motifs at the beginning of R3 and R4 domain[118]. Consequently, tau fibers 
may consist of protofibrils made up of juxtaposed β-sheets pairs. Ultimately, PHFs as a major 
variant and straight filaments as a minor variant[119] compose the neurofibrillary lesions in 
AD. They are revealed by electron microscopy as neurofibrillary tangles (NFTs) in cell bodies 
and apical dendrites, as neuropil threads in distal dendrites, and associated with some senile 
plaques in abnormal neurites. Neurons with NFTs degenerate and die, leaving within the 
neuropil a residual “ghost tangle” and glial cells[24]. If the Aβ plaques colonise rather 
synchronously predilection specific sites in the brain of AD patients, NFTs develop and 
spread in a predictable manner across the brain providing the basis for distinguishing six 
stages of disease progression: the transentorhinal Braak stages I-II represent clinically silent 
cases, the limbic stages III-IV correspond to incipient AD, and the neocortical stages V-VI are 
associated to fully developed AD (Figure 4C). 
 
A fascinating question still in debate is the mechanism(s) by which abnormal 
hyperphosphorylation of tau protein can lead initially to polymerisation into protofibrils 
(PHFs and straight filaments) and subsequently into the neurofibrillary lesions. Some 
hypotheses point up the role of other proteins as heparin sulphate and advanced glycosylation 
end-products[120]. Tau undergoes pathological posttranslational modifications such as 
truncation[121], glycosylation[122], glycation[123], ubiquitination[124], polyamination[125] and 
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nitration[126] that may modify its conformational properties and consecutively its physiological 
function and its ability to aggregate. 
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Figure 4. From tau gene to spread of neurofibrillary lesions in the brain of AD patients. (A) Schematic 
representation of the human tau gene and the six tau isoforms expressed in adult human brain. The human tau 
gene contains 16 exons, including exon 0 (E0), which is part of the promoter. E4a, E6 and E8 (stippled boxes) 
are not transcribed in the human central nervous system. Alternative mRNA splicing of E2 (pink box), E3 (green 
box) and E10 (yellow box) produce the six tau isoforms ranging from 352 to 441 amino-acids. They differ in the 
presence of 1, 2 or none N-terminal inserts (N1, N2) encoded by E2 and E3 and the presence of 3 or 4 
microtubule-binding repeat domains (R1 to R4, black bars) (adapted from Lee et al, 2001[3]). (B) Abnormally 
hyperphosphorylated tau aggregated into neurofibrillary lesions. (C) Neuropathological staging of AD according 
the development and spread of neurofibrillary lesions across the brain. Stages I/II correspond to clinical silent 
cases, stages III/IV represent the start of first clinical symptoms, and stages V/VI are associated to severe 
dementia (from Braak and Braak, 1991[9]). 
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1.2. Mitochondria: a matter of life and death 
Mitochondria are essential organelles for cell survival. They are the “powerhouses of 
cells”, providing energy supply by oxidative reactions from nutritional sources[127]. This 
energy, stored in the form of ATP, is subsequently used for a large repertoire of functions like 
intracellular calcium homeostasis[128], cell cycle regulation, thermogenesis and synaptic 
plasticity[129]. However, as the Pandora’s Box, mitochondria are full of potentially harmful 
proteins and biochemical reaction centres. They may liberate a flood of toxic compounds such 
as reactive oxygen species (ROS) and participate to apoptotic signalling pathways[130].  
 
1.2.1. Pivotal role of mitochondria within cells  
Mitochondrial structure 
Mitochondria are cytoplasmic organelles composed of a double lipid membrane which 
structures four compartments, distinct by composition and function. The porous outer 
membrane (OMM) encompasses the whole organelle. It contains cholesterol and many 
proteins like import complexes[62, 131] and voltage-dependant anion channels (VDAC) 
responsible for the free passage of low molecular weight substances (up to 5000Da) between 
the cytoplasm and the intermembrane space (IMS). In contrast to the permeable OMM, the 
inner membrane (IMM), rich in cardiolipin, provides a highly efficient barrier to the flow of 
small molecules and ions, including protons. This membrane is invaginated into numerous 
cristae which increase greatly its surface area. It houses the respiratory enzymes, the cofactor 
coenzyme Q (ubiquinone Q) and many mitochondrial carriers[132]. All these proteins are 
necessary for ATP production. Between the two membranes, IMS contains pro-apoptotic 
proteins like cytochrome c[133], apoptosis-inducing factor (AIF)[134], Smac/Diablo, Endo G and 
Htra2/Omi[135]. Finally, it is in the matrix, bordered by IMM, which take place different 
metabolic pathways including the tricarboxylic acid (TCA) cycle, also known as the Kreb's 
cycle and the beta-oxidation[130, 136]. The mitochondrial genome responsible for the limited 
genetic autonomy of mitochondria is also located in the matrix. 
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Mitochondrial respiratory capacity  
Although mitochondria are sites of many biosynthetic and metabolic processes, ATP 
production is paramount. They generate more than 90% of our cellular energy by two closely 
coordinated metabolic processes: TCA and the oxidative phosphorylation system (OXPHOS). 
 
TCA, composed of 8 enzymatic steps, is able to convert carbohydrates and free fatty 
acids into ATP. However, its major role consists to yield electrons in the form of reduced 
hydrogen carriers, the nicotine adenine dinucleotide (NADH) and the flavin adenine 
dinucleotide (FADH2). These 2 compounds, also produced in the cytosol and shuttled into 
mitochondria, enter subsequently as coenzymes into OXPHOS also called the mitochondrial 
respiratory machinery[137] (Figure 5A). 
 
OXPHOS is made up of the electron transport chain (ETC) formed of more than 85 
proteins and assembled in four enzymes (complex I to IV) as well as the F1F0-ATP synthase 
corresponding to the last complex (complex V). Complex I (NADH:ubiquinone 
oxidoreductase), complex III (ubiquinone:cytochrome c oxidoreductase) and complex IV 
(cytochrome c oxidase or COX)[138] are located in IMM as integral proteins whereas complex 
II (succinate dehydrogenase) which catalyses one of the TCA steps is attached to the inner 
surface of IMM. These five enzymes are connected functionally by mobile electrons acceptors 
and donors: ubiquinone and cytochrome c. In addition to flavins and nicotinamides, they 
utilize cytochromes, iron-sulfur clusters and copper centres to transfer electrons in a series of 
oxidation reduction steps (Figure 5A). Briefly, electrons from NADH and FADH2 feed into 
complex I and II respectively. Ubiquinone Q carries electrons from both complexes to 
complex III and cytochrome c transports ultimately electrons from complex III to IV reducing 
the molecular oxygen (O2) to water[139, 140]. As electrons are transferred along ETC, a fixed 
number of protons are pumped from the mitochondrial matrix into IMS, which establishes a 
proton electrochemical gradient (the proton motive force, ∆P) across IMM[141]. Two 
components define ∆P: a difference in the concentration of protons (∆pH, alkaline inside) and 
a difference in the electrical potential (negative inside: ∆ψ: −150 to −180 mV). The redox 
energy drives the synthesis of ATP from ADP and inorganic phosphate (Pi) by ATP synthase 
as protons are transported back from IMS into the mitochondrial matrix[138, 140, 142, 143]. ATP is 
then made available to the cell for various processes requiring energy. However, the 
consumption of NADH and FADH2 and the pumping out of protons from the mitochondrial 
matrix on one hand are not perfectly coupled with proton re-entry and ATP synthesis on the 
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other hand. The result is a proton leak mediated in part by specific inner membrane proteins, 
the uncoupling proteins (UCPs)[144-146] and dissipated as heat[147]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial DNA  
Current theory holds that mitochondria are descendants of aerobic bacteria that 
colonized an ancient prokaryote about 1.5 billion years ago[138, 148, 149]. This union may lead to 
the first eukaryotic cell capable of aerobic respiration, indispensable precursor to the 
evolution of current multicellular organisms[148]. This idea is supported by the fact that 
mitochondria are the only organelles in animal cells that possess their own genome. Each 
mitochondrion contains 2–10 copies of mitochondrial DNA (mtDNA) located in the 
matrix[150]. In every human cell except mature erythrocytes[151], 200 to 2000 mitochondria are 
found[152, 153]. The mtDNA copy number as well as the number of mitochondria per cell is 
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Figure 5. The mammalian oxidative phosphorylation system (OXPHOS) and the mitochondrial genome. 
(A) Simplified view of the mitochondrial oxidative phosphorylation system (OXPHOS). Complexes I 
(NADH:ubiquinone oxidoreductase) and II (succinate dehydrogenase, belongs to the tricarboxylic acid cycle 
called TCA) receive electrons from NADH and FADH2 respectively. Electrons are then driven from complexes 
by the mobile carrier molecules coenzyme Q/ubiquinone (UQ) and cytochrome c (Cyt c) to the final acceptor, 
molecular oxygen (O2). Electron flow is coupled to proton movement across the inner membrane (IMM) in 
complexes I, III and IV. The resulting proton gradient is harvested by complex V to generate ATP. (B) 
Schematic representation of the mammalian mitochondrial genome (16,569 bp). Mitochondrial DNA encodes 22 
tRNA genes (light-blue), two ribosomal RNA genes (dark-blue) and 13 genes encoding polypeptides of complex 
I (ND1-ND6), complex III (cytB), complex IV (COX1-3) and complex V (ATP6/8) (adapted from da Fonseca et 
al, 2008[8]). 
 
 14 
exquisitely calibrated on the cell type and the cellular energy demand. The largest number of 
mitochondria is found in the most metabolically active tissues like muscles, liver and 
brain[154]. The latter consumes 20% of the total oxygen supply while it accounts for only 2% 
of the total body mass[155].   
 
The mtDNA is a circular double-stranded molecule maternally heritated[156] (Figure 
5B). The outer strand is a guanine-rich heavy strand and the inner strand is a cytosine-rich 
light strand. The mtDNA contains 37 genes (16,569 base pairs) and codes for 13 proteins 
which all belong to the five respiratory enzymes complexes. It consists in 7 of 46 subunits 
constituting complex I (ND1, 2, 3, 4, 4L, 5, and 6), 1 of 11 subunits of complex III 
(cytochrome b), 3 of 13 subunits of complex IV (COX1, COX2 and COX3), and 2 of 17 
subunits of complex V (ATPase 6 and ATPase 8)[150]. In addition, the mitochondrial genome 
encodes the 12S and 16S ribosomal RNAs as well as 22 transfer RNAs[157] required for 
intramitochondrial protein synthesis. However, as only few mitochondrial proteins are 
encoded internally, the organelle is not liberated from the nuclear genes control. Complexes I, 
III and IV are encoded by both mtDNA and nuclear DNA (nDNA), while complex II is 
carried out exclusively by nDNA[158]. Furthermore, most of the proteins building 
mitochondria and these forming the mitochondrial machinery like metabolic enzymes, DNA 
and RNA polymerases, ribosomal proteins, and mtDNA regulatory factors (e.g. mitochondrial 
transcription factor A) are imported from the cytosol[159]. The import is mainly accomplished 
by membrane spanning, multi-subunit translocators of OMM and IMM.  
 
Unlike nDNA, mtDNA is not protected by histones[160] making it more vulnerable to 
injury as oxidative stress[161] and its mutation rate is about 10-fold higher than this of 
nDNA[162], especially in tissues with a high ATP demand like the brain. To mitigate mutation 
risks, mitochondria develop an inheritance which greatly differs from the Mendelian mode of 
nDNA[163]. First, mitochondria are distributed to daughter cells more or less randomly during 
cell division. Most importantly, mitochondria divide mainly in response to cellular energy 
needs, independently of cell cycle. In other words, when a cell needs high energy, 
mitochondria grow and divide, and when the cell uses low energy, they are destroyed or 
become inactive. For example, the mitochondrial genome replicates regularly in postmitotic 
cells, about once per month[136] in order to maintain the mitochondrial function in neurons[164]. 
Finally, mitochondria continuously divide and fuse with each other, forming a veritable 
network. Although incompletely understood, the combined consequence of all the processes 
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is mtDNA recombination and both normal and modified mitochondrial genes in a cell [136, 164]. 
The deleterious effects of mitochondrial mutations are reduced and the potential for the 
removal of modified mtDNA by autophagy increases. However, during ageing or in 
pathological case, these mechanisms may be altered and lead to mitochondrial alterations. 
Above a certain threshold (“threshold effect”) they drive to respiratory and metabolic defects 
getting progressively worse. Since 1962 such impairments are associated with a wide range of 
severe human disorders regrouped under the name of mitochondrial diseases[165-167].  
 
1.2.2. Mitochondria as sources and targets of reactive oxygen species  
The fate of most electrons from NADH or FADH2 driven in the respiratory chain is 
the reduction from O2 to water at complex IV. Mitochondria consume approximately 85% of 
O2 utilized by cells during ATP production[168]. However, this elegant system for energy 
production is not perfect. A small portion of electrons (up to 2%) escaping from ETC, mostly 
at complexes I and III[169, 170], react with O2 and yield superoxide anion (O2-.)[168, 171, 172], which 
can be converted into other ROS such as hydrogen peroxide (H2O2) and the highly reactive 
hydroxyl radical (OH.) through enzymatic and nonenzymatic reactions[173-175] (Figure 6). 
Although, ETC is the major source, radicals may be generated by peroxisomes as well as a 
variety of cytosolic enzymes systems (e.g. xanthine oxidase, mitochondrial monoamine 
oxidase (MAOA and MAOB), nitric oxide synthase (NOS), and NADPH oxidase)[176]. In 
addition, a number of external agents (e.g. toxins, chemotherapeutics and radiations) can 
trigger ROS[176].  
 
Cells are endowed with robust endogenous antioxidant systems to counteract 
excessive ROS. O2-. is detoxified first to H2O2 by manganese superoxide dismutase (MnSOD) 
or copper/zinc superoxide dismutase (Cu/Zn SOD)[138] and then to water by glutathione 
peroxidase (GPX) or catalase (CAT)[177] (Figure 6). In addition to enzymes, low molecular 
weight antioxidants acting either indirectly as chelating agents or directly like the glutathione 
(GSH), NADPH and nutritional products (ascorbic acid, lipoic acid, polyphenols and 
carotenoids)[178, 179] regulate overall ROS levels to maintain physiological homeostasis. 
Interestingly, recent data suggest that neuronal UCPs proteins by regulating ∆ψ[146] may 
reduce ROS production.  
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It is believed that ROS, in particular O2-. and H2O2, have roles as signalling 
molecules[180, 181] in physiological processes including defense against infection and 
coordination of inflammatory responses as well as synaptic plasticity, learning and 
memory[182]. However, when ROS production overwhelms endogenous antioxidant systems, 
they can lead to harmful effects on cellular compounds, inducing lipid peroxidation and 
proteins and DNA oxidation[183] (Figure 6). These injuries are collectively referred to as 
“oxidative stress”. Become the main target of ROS attacks is the price to pay by mitochondria 
for being the major source[178, 184-186]. The long polyunsaturated fatty acid chains of 
mitochondrial membranes are very susceptible to oxidation and may lead to the membrane 
depolarization and consecutively to mitochondrial impairments[169]. O2-., produced by 
complex I and III, damages the iron-sulfur cluster that resides in the active site of aconitase, a 
TCA enzyme[187]. Nitric oxide (NO.) produced by the mitochondrial nitric oxide synthase 
(mtNOS)[172] and also freely diffuses into mitochondria from the cytosol[177] reacts with O2-. to 
produce peroxynitrite (ONOO−)[177]. This latter is a reactive molecule that can induce nitration 
of proteins on tyrosine residues and impair their function[188]. Unlike ONOO− which 
inactivates multiple mitochondrial enzymes, NO. inhibits specifically and reversibly the 
complex IV activity by competitive binding on its oxygen site[189]. In parallel, mtDNA 
localized close to ROS production sites is vulnerable to oxidative damage as well. Oxidized 
guanosine levels are higher in mtDNA than in nDNA[162]. Taken together, oxidative damages 
of the mitochondrial compounds lead to a shutdown of energy production[166], which in turn, 
leads to a decrease of antioxidant defense (e.g. GSH) and the enhancement of ROS triggering 
the vicious cycle of oxidative stress, mitochondrial dysfunction and apoptosis. First states in 
the theory of aging[190, 191], the mitochondrial “vicious cycle” has been thereafter implicated in 
many degenerative diseases, most of them affecting the brain and muscles which are high 
energy consumers[192].  
 
Of note, a major unsolved and still controversial issue is whether increased ROS 
production is a primary consequence of mitochondrial dysfunction or whether a primary 
defect in ROS scavenging activity is responsible for an abnormal respiratory function. This 
point is particularly challenging in many pathological cases in order to establish clear cause 
and effect relationship. 
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1.2.3. Mitochondria-dependent apoptosis 
Although paradoxical with regards to their indispensable role on cell survival, 
mitochondria are also implicated in both widely recognized cellular demises namely the 
programmed cell death (apoptosis) and the accidental cell death (necrosis). During necrosis, 
cells are caught ‘‘off guard’’ by severe injuries and lead to nonselective cell damage. 
Conversely to necrosis, during apoptosis cells ‘‘decide’’ to die and activate molecular suicide 
cascades producing and mobilizing many proteins considered as executioners. While 
apoptosis plays an essential role in regulating growth and development, its misregulation may 
give rise to a series of pathological states[193]. Interestingly, it is not uncommon for one 
effector, such as oxidative stress to have the capacity to trigger a combination of apoptosis 
and necrosis[5]. For example, oxidative stress-dependent mitochondrial membrane 
permeabilization (MMP) may constitute a common event of both death modalities[5] and the 
exhaustion of ATP supply by apoptotic mechanisms may lead to necrosis[129]. 
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Figure 6. Pathways of reactive oxygen species (ROS) formation and their enzymatic detoxification. 
Complexes I and III generate superoxide anion radical (O2-.) during the electron transfer process. O2-. can interact 
with NO., produced by nitric oxidase synthase (NOS), to generate peroxynitrite (ONOO-). The enzymatic 
activity of mitochondrial manganese superoxide dismutase (SOD) converts O2-. to hydrogen peroxide (H2O2), 
which may then diffuse to the cytoplasmic compartment where glutathione peroxidase (GPX) and catalase 
convert H2O2 to H2O. H2O2 can interact with Fe2+ or Cu+ to generate hydroxyl radical (OH. ), a highly reactive 
free radical, that can induce as well as ONOO-, lipid peroxidation and oxidative damage to protein and DNA. Of, 
note, NO.  and its derivates (reactive nitrogen species or RNS) belong also to the group of ROS.  
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Apoptosis results from two biochemical cascades, known as the extrinsic and 
mitochondrial pathways (Figure 7A and B). Mitochondrial apoptosis is caused by several 
conditions of intracellular stress, such as oxidative stress and Ca2+ overload. Holding many 
pro-apoptotic proteins, the structural and functional alterations of mitochondria have major 
impact on cellular viability[194, 195]. As mentioned previously (see paragraph 1.2.2), 
mitochondria are very vulnerable to oxidative stress which may lead to ∆ψ decrease[196], ETC 
impairment and ATP depletion[5, 189]. When these lethal signals predominate to pro-survival 
mechanisms attempted by the cell to cope the stress, mitochondrial membranes are 
permeabilized (MMP)[197]. This phase determines whether the cell will succumb to or survive 
the injury, and represents a “point of no return” in the mitochondrial cell death. Although still 
debated, the opening of the permeability transition pore complex, constituted of several 
transmembrane proteins, may break irreversibly ∆ψ down and induce MMP[5]. Bioenergetic 
and biosynthetic functions of mitochondria are consequently stopped and proteins like 
cytochrome c and AIF[198] regulated by pro- (bax, bak, bad, bim, bid) and anti-apoptotic 
proteins (bcl-2 and bcl-xl) of the Bcl-family[199] are released from IMS into the cytosol. The 
mechanism by which cytochrome c activates the apoptotic cascade remains to be fully 
elucidated. However, it seems to participate in the formation of a multiprotein complex called 
apoptosome. The complex activates initiator caspases (caspase 8 and 9) and transduces lethal 
signals by catalysing the proteolytic maturation of executioner caspases (caspase 3, 6 and 7) 
and pro-apoptotic factors (BH3-only protein BID). Finally, executioner caspases cleave 
numerous intracellular substrates contributing to the catabolic phase of cell death[195, 198] 
(Figure 7B). 
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Figure 7. The extrinsic and intrinsic (mitochondrial) pathways of apoptosis. (A) The extracellular apoptotic 
pathway is initiated at the plasma membrane by specific transmembrane receptors, whereas (B) the 
mitochondrial apoptosis is triggered by intracellular stimuli such as Ca2+ overload and overgeneration of reactive 
oxygen species (ROS). In both pathways, initiator caspases (caspase 8 and 9) are activated within specific 
supramolecular platforms and so can catalyse the proteolytic maturation of executioner caspases, such as caspase 
3, which mediate (at least part of) the catabolic processes that characterize end-stage apoptosis. Mitochondrial 
membrane permeabilization (MMP) marks a point of no return in the mitochondrial pathway by activating both 
caspase-dependent and caspase-independent mechanisms that eventually execute cell death. For example, 
following MMP the mitochondrial intermembrane space (IMS) protein cytochrome c (CYT C) is released into 
the cytosol and interacts with the adaptor protein apoptotic peptidase activating factor 1 (APAF1) as well as with 
procaspase 9 to form the apoptosome. This results in the sequential activation of caspase 9 and executioner 
caspases, such as caspase 3, which lead to apoptotic features like cell shrinkage and DNA fragmentation. One of 
the major links between extrinsic and mitochondrial apoptosis is provided by the BCL-2 homology domain 3 
(BH3)-only protein BID, which can promote MMP following caspase-8-mediated cleavage. dATP, 
deoxyadenosine triphosphate; DISC, death-inducing signalling complex; tBID, truncated BID (adapted from 
Galluzzi et al, 2009[5]). 
A B 
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1.3. Mitochondrial dysfunction in Alzheimer’s disease 
Although, our understanding of AD made tremendous strides in the last decades, its 
molecular pathogenesis is not clearly established yet, particularly the mechanisms occurring 
in the early phase of the disease. Interestingly, positron emission tomography (PET) 
measurements demonstrate reduced energy metabolism in affected brain regions of AD 
patients and suggest that cellular energy deficit may precede cognitive symptoms[200] (Figure 
8). In line with this idea, oxidative stress and mitochondrial abnormalities are estimated to 
occur before the onset of Aβ aggregates, tau pathology, synaptic dysfunction and 
inflammation in AD brain[201-207]. Markers of proteins and mtDNA oxidative damages as well 
as lipid peroxidation products (e.g. malondialdehyde (MDA) and 4-hydroxynonenal 
(HNE))[208] have been found in cortical lesions of AD patients[62, 209, 210], cybrid cells[211] and 
transgenic mice[203, 212-214]. Increased free radical generation has also been observed in 
mitochondria from peripheral cells of AD patients like platelets, fibroblasts and 
lymphocytes[136, 192, 215]. Decreased activities of mitochondrial enzymes including pyruvate 
dehydrogenase, α-ketoglutarate dehydrogenase and COX have been reported[216, 217]. Finally, 
some authors propose that mitochondrial machinery impairments[218, 219] and axonal transport 
defects[220] may be directly responsible for the synaptic failure and the cell death observed in 
AD.  
 
The causal factors of mitochondrial alterations in cells of AD patients have to be 
clarified, but may involve aging, AD-related proteins and oxidative stress leading to reduced 
synaptic/cellular energy availability and ultimately to cortical neurodegeneration. Moreover, 
the critical role of mitochondria on the early pathogenesis of AD makes them into a 
preferential target for treatment strategies including antioxidants such as Ginkgo biloba 
extract (GBE). 
 
 
 
 
 
 
 
 
                                            Normal brain      AD brain 
 
Figure 8. Major reductions in cellular energy metabolism in living AD patients. Positron emission 
tomography images show glucose uptake (red and yellow indicate high levels) in a normal control subject. AD 
patient exhibits large decreases in energy metabolism in the frontal cortex (top of brain) and temporal lobes 
(sides of the brain) (from Mattson, 2004[1]). 
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1.3.1. Link between Aβ toxicity and mitochondria 
Ever since Aβ peptide was discovered, substantial research has focused on 
understanding its toxicity in brain of AD patients. Few years ago, it has been proposed that 
toxic species of Aβ intervening in molecular and biochemical abnormalities may be 
intracellular, oligomeric forms instead of extracellular, insoluble plaques[221, 222]. Aβ 
oligomers can inhibit long-term potentiation (LTP), a model system for synaptic plasticity and 
memory[223]. The presence of intracellular Aβ and synaptic alterations observed long before 
plaques formation in AD patients[224] and in several transgenic mouse models[225-227] have 
been acknowledged by the modification of the classical “amyloid cascade hypothesis”[6, 228] 
(Figure 9). Importantly, the “intracellular hypothesis” points up the role of mitochondria in 
the mechanism by which intracellular Aβ triggers synaptic failure and neurodegeneration[4, 229, 
230]
 and correlates with studies recognizing energy metabolism deficiencies as earliest events 
in AD[231].  
 
A time course investigation of Aβ and free radical production revealed that H2O2 
formation correlates significantly with soluble Aβ but not insoluble Aβ, suggesting that in AD 
progression, soluble Aβ may enter mitochondria and induce ROS[214]. In accordance with this 
idea, some studies showed that oligomeric Aβ, with its sharp morphology, may have the 
ability to permeabilize cellular membranes and lipid bilayers thereby entering organelles, such 
as mitochondria[232, 233]. Recently, accumulation of Aβ inside mitochondria has been  
proved[62, 234-236] and associated to functional[237-240] as well as structural mitochondrial 
impairments[201] in several cellular and transgenic mouse models. Aβ can disrupt 
mitochondrial COX activity in a sequence- and conformer-dependent manner[234, 241]. An 
interaction between a mitochondrial matrix enzyme called the Aβ binding protein alcohol 
dehydrogenase (ABAD) and Aβ in AD brain and animal models[242] confirmed the Aβ intra-
mitochondrial hypothesis. Aβ-ABAD complex impairs the binding of NAD to ABAD, 
changes mitochondrial membrane permeability[243] and reduces activities of respiratory 
enzymes[236] leading to mitochondrial failure. Finally, the interaction between Aβ and 
mitochondria may explain how Aβ induces apoptosis and caspase activation[236, 244, 245]. The 
way by which Aβ reaches mitochondria is still debated. Aβ may be internalized by cells, 
imported into mitochondria via the translocator outer membrane (TOM) complex and 
accumulated in cristae[61]. A second mechanism may implicate an intracellularly generation of 
Aβ[246-248]. Of note, some authors propose that Aβ precursor, APP, may block mitochondrial 
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import channels preventing the import of nuclear-encoded COX (complex IV) subunits IV 
and Vb[213] which decreases its activity and increases ROS production[62].  
 
Collectively, these studies suggest that Aβ enters mitochondria and interacts with 
mitochondrial proteins, disrupts ETC, generates ROS leading ultimately to the drop of ATP 
levels[154]. The presence of intracellular Aβ adds a further level of complexity to the 
mechanism of Aβ toxicity as this enables direct access to organelles that are vital for the 
function and viability of neurons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2. Effects of tau protein on mitochondrial function and axonal transport  
For a long time, the “amyloid cascade hypothesis” claiming that in the pathogenic 
cascade of AD, Aβ is upstream of tau was an authority[249]. However, a recent theory 
declaring an Aβ-independent tau toxicity has seen the light[250]. The accumulation of NFTs 
occur in many neurodegenerative diseases referred to as “tauopathies”[251, 252] including AD. 
However, in contrast to AD, in many of these disorders, NFTs are abundant in the absence of 
overt Aβ plaques[3] suggesting a sufficient role of tau pathology to induce the 
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decreased clearance, enhanced aggregation)
Aβ42 oligomerization and initial Aβ42 deposits
subtle effects of Aβ42 oligomers on synaptic function
progressive synaptic/neuronal injury
altered neuronal ionic homeostasis, oxidative injury
altered kinase/phosphatase activities → tangles
dementia with plaques and tangles pathology
widespread neuronal dysfunction and cell death
associated with neurotransmitter deficits
inflammatory responses (microglia and astrocytes activation)
Aβ plaques formation
 
 
Figure 9. The amyloid cascade hypothesis. The cascade is initiated by the generation of amyloid-β42 (Aβ42). In 
AD familial early onset (FAD), Aβ42 is overproduced owing to pathogenic mutations. In sporadic AD (SAD), 
various factors can contribute to an increased load of Aβ42 oligomers and aggregates. Amyloid-β oligomers 
might directly injure the synapses and neurites of brain neurons, in addition to activating microglia and 
astrocytes. Tau pathology, which contributes substantially to the disease process through hyperphosphorylated 
tau and tangles, is triggered by Aβ42 (adapted and modified from Selkoe et al, 2002[6]). 
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neurodegeneration. Interestingly, oxidative stress and mitochondrial dysfunction have been 
proposed as key events within this tau pathology in these diseases including AD.  
 
In AD, oxidative stress may lead to the phosphorylation of tau either by direct oxidative 
damages like HNE inducing tau conformational changes and NFTs formation[253, 254], or by 
deregulating proteins like ERK2 known to play a crucial role in the phosphorylating 
process[255]. In recent studies, it has been showed that misregulation of tau causes ATP 
depletion in synapses and enhancement of oxidative stress, long before tau detaches from 
microtubules and aggregates into NFTs[256-258]. Subsequent abnormal hyperphosphorylation of 
tau compromises the stability and function of microtubules which emphasizes the 
mitochondrial trafficking decrease and ATP starvation in nerve terminals[259] which may lead 
to neurotransmission impairments. Finally, NFTs formation leads to the progressive loss of 
axonal or dendritic transport[260]. Moreover, our group demonstrated mitochondrial 
dysfunction by proteomic and functional analyses[239] in a new tau transgenic mouse 
model[261]. The mice overexpressing the P301L mutant human tau protein exhibit an 
accumulation of hyperphosphorylated tau already at 3 months old and develop NFTs from 6 
months old[261]. Mainly mitochondrial proteins, antioxidant enzymes and synaptic proteins 
were deregulated in the proteome pattern of P301L tau mice[239]. Functional analysis showed 
reduced complex I activity as well as impaired mitochondrial respiration and ATP synthesis 
with age. Mitochondrial dysfunction was associated with higher levels of ROS in aged 
transgenic mice. In addition, increased tau pathology revealed modified lipid peroxidation 
levels and up-regulation of antioxidant enzymes in response to oxidative stress[239]. For the 
first time, it has been proved that not only Aβ but also tau accumulation act on brain 
metabolism and oxidative conditions in AD.  
 
Taken together, this evidence supports a role of Aβ-free tau pathology on 
mitochondrial and metabolic dysfunction. Tau toxicity may act indirectly by modifying 
microtubule stability, axonal transport and mitochondrial network. A second mechanism may 
be a direct inhibition of energy production by the rise of oxidative stress and impairment of 
respiratory enzymes as suggested by the accumulation of increasingly insoluble ATP synthase 
α-chain together with NFTs in AD brains whereas detergent soluble levels were reduced[262]. 
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1.3.3. Aβ and tau share mitochondria as a common target  
‘‘The genetics of Alzheimer’s disease favours a link to amyloid-beta but the clinical picture 
favours a link to tau neurofibrillary tangles.’’ M. Mesulam (International Conference on 
Alzheimer's Disease, 2008)  
 
Although both Aβ and tau pathologies are common features in AD, it is still 
mysterious how they relate to each other. Some authors established that Aβ injections 
exaggerate a pre-existing tau pathology of several transgenic mouse models[261, 263-265]. 
Interestingly, recent evidence suggests that Aβ toxicity is also tau-dependent. Reducing 
endogenous tau levels prevented behavioral deficits as assessed in the Morris water maze, 
without altering Aβ levels[266]. Earlier findings in cultured hippocampal neurons derived from 
tau knockout and transgenic mice support the model that tau is required for Aβ-induced 
neurodegeneration[267]. Taken together, the studies illustrate a complex interplay between the 
two key proteins showing abnormal behavior in AD. 
 
In parallel, increasing evidence suggests a role for mitochondrial alterations upstream 
of both Aβ and tau pathologies in AD. Moreover, close relationship between mitochondrial 
failure and Aβ on one hand, and tau on the other hand have been demonstrated (see 
paragraphs 1.3.1 and 1.3.2). Thereby, could be mitochondria the point of convergence of the 
two unquestionable pathologic hallmarks of the disease? Recent findings are in line with this 
hypothesis. Aβ aggregates and hyperphosphorylated tau may block the transport of 
mitochondria leading to energy deprivation at the synapse and neurodegeneration[257, 258]. 
Moreover, elevated tau may inhibit the transport of APP into axons and dendrites, causing 
impaired axonal transport suggesting a linkage between tau and APP[101, 268]. In addition, 
functional genomics encompassing transcriptomic and proteomic approaches[269-272] showed 
that Aβ treatment together with human tau over-expression in a cell culture model affected the 
regulation of genes controlling cell proliferation and synaptic elements in AD[273, 274].  
 
In summary, these findings exemplify interactions between Aβ and tau at the 
mitochondria level, nevertheless many questions are still unresolved. How tau pathology 
mediates these changes and its role within the amyloid cascade remains unclear. The precise 
impacts of both lesions on mitochondrial respiratory machinery and energy homeostasis are 
still outstanding. 
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1.3.4. Transgenic mouse models  
Understanding the molecular pathways by which the various pathological alterations 
including Aβ and tau, compromise neuronal integrity and lead to clinical symptoms has been 
a long-standing goal of AD research. Success in developing mouse models that mimic divers 
facets of the disease process has greatly facilitated this effort[2, 7, 35].  
 
In 1995, Games and co-workers established the first Aβ plaque-forming mouse model 
by targeting high levels of the disease-linked V717F mutant form of APP in brain, using the 
platelet-derived growth factor (PDGF) mini-promoter for expression[275]. These PDAPP mice 
showed many of AD pathological features, including extensive deposition of extracellular 
amyloid plaques, astrocytosis and neuritic dystrophy[275]. Subsequently, a lot of APP-based 
transgenic models have been developed[276-280] and instrumental in addressing aspects of Aβ 
toxicity and age-dependent cognitive decline as well as testing therapies like vaccination 
trials[281, 282] (Figure 10A and B). The same year, Gotz and colleagues established the first tau 
transgenic mouse model, expressing the longest human brain tau isoform, without a 
pathogenic mutation and using the hThy1 promoter for neuronal expression[283]. Despite the 
lack of NFTs pathology, these mice modeled aspects of human AD, such as the 
somatodendritic localization of hyperphosphorylated tau and, therefore, represented an early 
“pre-NFTs” phenotype. Once the first pathogenic FTDP-17 mutations identified in the MAPT 
gene in 1998, several groups expressed them in mice. For example, the P301L tau-expressing 
pR5 mice develop aggregated forms of hyperphosphorylated tau and NFTs as well as 
neuronal loss[261, 284-286]. Moreover, these mice showed age-related behavioral impairment in 
amygdala- and hippocampus-dependent tasks which could be correlated with the aggregation 
pattern of the transgene[287, 288] (Figure 10A and B). Finally, the discovery of FAD mutations 
in the presenilin (PSEN) genes which influence APP processing, opened the path for PSEN1 
and PSEN2 transgenic mouse models, and double-cross APP/PSEN models[35]. Recently, 
double[264, 289] and triple[225, 290, 291] transgenic mice combining Aβ and tau pathologies in one 
model have been generated (Figure 10A). The latest triple transgenic mouse line termed 
tripleAD co-expresses mutated tau (P301L), PS2 (N141l) and APPSwe (KM670/671NL). This 
model complements a first triple transgenic mouse model[292] harboring the PS1M146V instead 
of the previous PS2 mutation. In this model with plaques and tangles, behavioural and 
neuronal symptoms of AD were already reported including synaptic dysfunction and LTP 
deficits[293]. However, a molecular link between Aβ and tau protein in AD pathology was still 
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missing in vivo. Moreover, while recent findings indicated an interplay between PS1 and PS2 
on mitochondrial functionality, more relevantly a specific role for PS2/γ-secretase on these 
organelles has been highlighted[294]. Finally, tripleAD mice are the only known model to 
develop both tau and amyloid deposits in an age-dependent manner. NFTs pathology starts at 
4 months old in contrast to other models developing substantial NFTs pathology very later, at 
18-24 months old[292, 293]. The tripleAD model is therefore particularly suited to study 
relationship between Aβ and tau in an age-related way. It has been shown, for example, that 
Aβ accumulation leads to the development of tau phosphorylation at a specific AD-epitope 
(Ser422). Although, the mice do not develop extensive neuronal loss or pronounced cognitive 
deficits, the progression of biochemical changes and histopathological features is reminiscent 
of the pathogenesis course observed in AD. Consequently, the model may be very useful for 
assessing therapeutic interventions addressing amyloidosis and/or Tau pathology. 
Importantly, behavioral deficits are present before detection of any protein aggregates which 
is especially meaningful considering the paradigm of the early mitochondrial dysfunction 
reported in AD.  
 
It has been over a decade since the first AD transgenic mouse models have been 
reported. These models have enabled dramatic advances in our understanding of the 
pathogenic mechanism in AD and potential therapeutic approaches to tackling the inexorable 
clinical progression of the disease. Many of new therapeutic strategies have their foundation 
in transgenic animal work[2]. In this vein, the recent triple transgenic mice are not only 
promising in order to understand the complex interplay between Aβ and tau at the 
mitochondrial level in vivo but also to assist in the development of new treatments more 
adapted and efficient towards AD. 
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Figure 10. Reproducing plaques and NFTs in transgenic mice. (A) Plaques are produced by expressing 
mutant amyloid precursor protein (APP), as found in patients with familial Alzheimer’s disease (FAD), both 
with and without mutant PSEN1. Neurofibrillary tangles (NFTs) are produced by expressing mutant tau, as 
found in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17). A few 
exemplary mutations are listed (grey boxes) together with their strain names and the promoters (in brackets) that 
were used for expression. (B) Progression of the pathology in APP23 and pR5 mice. NFTs formation in pR5 
mice is initiated in the amygdala and eventually found in the hippocampus, whereas the cortex is virtually 
spared. Plaque formation in APP23 mice is prominent in the cortex and in the hippocampus. This reflects, to 
some extent, the situation in the brain of patients with AD, in which plaques and NFTs are anatomically 
separated (from Gotz and Ittner, 2008[7]). 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
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1.3.5. Ginkgo biloba extract for the treatment of Alzheimer’s disease  
There is no cure for AD and the available treatments (e.g. acetyl cholinesterase 
inhibitors (tacrine, donepezil, rivastigmine and galantamine) and N-methyl-D-aspartate 
(NMDA) antagonist (memantine)) are only symptomatic. However, the increasing body of 
evidence implicating oxidative stress and mitochondrial dysfunction in the pathogenesis of 
AD raises the possibility of the beneficial use of antioxidants. The hypothesis is particularly 
promising owing to numerous free radical scavengers are known and many including Ginkgo 
biloba extract (GBE) have no major side effects. GBE is a valuable therapeutic drug for the 
treatment of memory impairment and dementia including AD. Double-blind, placebo-
controlled studies showed the improvement of cognitive symptoms in the elderly and in AD 
patients[295-299]. 
 
Standardized GBE, obtained from dried green whole leaves of Ginkgo biloba tree with 
acetone/water mixture, is defined as dried extract (drug-extract ratio 35-67:1). Different 
standardized GBE are on the market, e.g. EGb 761 (Schwabe Firm, Germany, Tebokan® in 
Switzerland) and LI 1370 (Vifor Firm, Switzerland, Symfona®)[300]. The most studies refer to 
EGb 761 as yet. GBE consists in two major groups of substances, flavone glycosides 
(flavonoid fraction, 22-27%) and terpene lactones (terpenoid fraction, 5-7%). Ginkgolic acids 
are reduced to at most 5ppm[301]. The flavonoid fraction is primarily composed of quercetin, 
kaempferol and isorhamnetin glycosides, and the terpenoid fraction of ginkgolides A, B, C, J 
and M (2.8-3.4%) as well as bilobalide (2.6-3.2%)[302] (Figure 11). The chemical structure of 
flavonoids preferentially reacts with hydroxyl radicals[303] and chelate pro-oxidant transition 
heavy metal ions[304], which consequently inhibits the formation of new hydroxyl radicals. 
Ginkgolides are known to be platelet activating factor (PAF) antagonists, able to improve 
blood circulation[305] and cerebral insufficiency[306]. Although individual constituents have 
been found to be active in a variety of assays, mechanisms underlying GBE beneficial effects 
may reside in the synergistic action of all components. 
 
Substantial in vitro and in vivo models demonstrated free radical scavenger activity 
and anti-apoptotic properties of GBE[302, 307-310]. In addition to its intracellular antioxidant 
properties, GBE may stabilize directly mitochondrial function. Our group showed that GBE 
improves ∆ψ and ATP levels, and protects mitochondrial respiratory complexes in stress 
models[311-313]. Of note, the ginkgolide J, the flavonoid fraction and the bilobalide were the 
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most effective to stabilize ∆ψ in this study. These effects may lead to a decrease of ROS 
production and cell death processes. In accordance with this idea, the transcript level for an 
anti-apoptotic Bcl-2-like protein was elevated, whereas the transcript level for pro-apoptotic 
caspase 12 was decreased in PC12 cells treated with GBE[310, 314]. In addition, enhancement of 
tau mRNA expression in cortex of mice whose diets were supplemented with GBE has been 
observed[315]. Interestingly, recent studies suggest that GBE may develop an 
antiamyloidogenic property inhibiting amyloid fibrils formation either by a direct interaction 
with Aβ[316, 317] or by activating α-secretase pathway[318]. It is assumed that GBE anti-
oxidative properties combined to its action on AD-related proteins may protect the brain 
against the cognitive dysfunction observed in the disease. Moreover, GBE may improve the 
neurotransmission[319] as well as the neuronal plasticity[304] and develop anti-inflammatory 
effects[320]. In several aging and stress animal models, GBE enhanced the cognition, spatial 
learning and explorative behavior[321-323]. Clinical studies including meta-analyses and double-
blind trials supported also efficiency of GBE on cognitive defects, daily living and clinical 
global impression in dementia patients including AD[295-297, 324].  
 
Although, many animal models reports and clinical studies propose neuroprotective 
effects of GBE[318, 325], cellular and molecular mechanisms, specially these relating to 
mitochondrial respiratory function, remain unknown. The elucidation of biochemical 
pathways by which GBE exercises its polyvalent protective effects may not only open new 
ways for the development of more efficacious therapies but also ripen our understanding of 
mitochondria role within AD pathological processes. 
 
 
 
 
 
 
 
 
 
 
 
 
Flavonoids Ginkgolides Bilobalide
R1 R2
Kaempferol H H
Quercetin OH H
Isorhamnetin OCH3 H
Myricetin OH OH
R1 R2 R3 R4
Ginkgolide A H OH H OH
Ginkgolide B H OH OH OH
Ginkgolide C OH OH OH OH
Ginkgolide J OH OH H OH
Ginkgolide M OH H OH OH
Figure 11. Chemical structures of main constituents present in Ginkgo Biloba Extract (GBE). GBE consist 
in two major groups of substances: the flavonoid fraction (22-27%) composed of quercetin, kaempferol, 
isorhamnetin and myricetin, as well as the terpenoid fraction (5-7%) composed of ginkgolides A, B, C, J and M 
and bilobalide. 
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ABSTRACT 
 
Alzheimer’s disease (AD) is characterized by β-amyloid (Aβ)-containing plaques, 
neurofibrillary tangles, as well as neuron and synapse loss. Tangle formation has been 
reproduced in P301L tau transgenic pR5 mice while APPswPS2N141I double-transgenic 
APP152 mice develop Aβ plaques. Cross-breeding generates triple transgenic (tripleAD) mice 
that combine both pathologies in one model. To determine functional consequences of the 
combined Aβ and tau pathologies, we performed a proteomic analysis followed by functional 
validation. Specifically, we obtained vesicular preparations from tripleAD mice, the parental 
strains and non-transgenic mice, followed by the quantitative mass-tag labelling proteomic 
technique, iTRAQ, and mass spectrometry. Within 1275 quantified proteins, we found a 
massive deregulation of 24 proteins of which one third were mitochondrial proteins mainly 
related to complexes I and IV of the oxidative phosphorylation system (OXPHOS). Notably, 
deregulation of complex I was tau-dependent, while deregulation of complex IV was Aβ-
dependent, both at the protein and activity levels. Synergistic effects of Aβ and tau were 
evident in 8-month-old tripleAD mice as only they showed a reduction of the mitochondrial 
membrane potential at this early age. At the age of 12 months, the strongest defects on 
OXPHOS, synthesis of ATP and reactive oxygen species were exhibited in the tripleAD mice, 
again emphasizing synergistic, age-associated effects of Aβ and tau in perishing 
mitochondria. Our study establishes a molecular link between Aβ and tau protein in AD 
pathology in vivo illustrating the potential of quantitative proteomics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Aβ, β-amyloid peptide; AD, Alzheimer’s disease; APP, amyloid protein precursor; CS, citrate 
synthase; FTD, fronto-temporal dementia; GO, gene ontology; iTRAQ, isobaric tags for relative and absolute 
quantitation; LTP, long-term potentiation; MMP, mitochondrial membrane potential; NFT, neurofibrillary 
tangles; OXPHOS, oxidative phosphorylation system; ROS, reactive oxygen species; tripleAD, triple transgenic 
Alzheimer’s disease mice; wt, wild-type. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting more 
than 15 million people worldwide (1). The key histopathological features are β-amyloid-
containing plaques and microtubule-associated protein tau-containing neurofibrillary tangles 
(NFTs), along with neuronal and synapse loss in selected brain areas (2, 3). In determining the 
role of distinct proteins in these processes, traditionally, candidate-driven approaches have 
been pursued, linking neuronal dysfunction to the distribution of known proteins in healthy 
compared to degenerating neurons, or in transgenic compared to control brain. In comparison, 
proteomics offers a powerful non-biased approach as shown by us previously (4, 5).  
 
APP152 (APP/PS2) double-transgenic mice model the Aβ plaque pathology of AD 
(6); they co-express the N141I mutant form of PS2 together with the APPsw mutant found in 
familial cases of AD. The mice display age-related cognitive deficits associated with discrete 
brain Aβ deposition and inflammation (6). pR5 mice model the tangle pathology of AD (7-9). 
They express P301L mutant tau found in familial cases of frontotemporal dementia (FTD), a 
dementia related to AD. The pR5 mice show a hippocampus- and amygdala-dependent 
behavioural impairment related to AD (10). Crossing of pR5 and APP/PS2 mice produces 
tripleAD mice, with tau and Aβ levels comparable to the parental strains (11). 
 
Here, we performed a comparative, quantitative proteomic analysis of single-
transgenic pR5, double-transgenic APP/PS2 and tripleAD (pR5/APP/PS2) mice, as well as 
wild-type controls and found that one third of the deregulated proteins were mitochondrial. In 
evaluating our findings, we could establish mitochondrial dysfunction in tripleAD mice, 
synergistically induced by tau and Aβ pathologies.  
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RESULTS 
 
Comparative iTRAQ (isobaric tags for relative and absolute quantitation) mass-
spectrometry. Crude vesicular fractions of forebrains obtained from 10 months-old single-
transgenic pR5 mice, double-transgenic APP/PS2 mice, a cross of the two strains (tripleAD), 
and non-transgenic littermate controls were trypsin digested, and peptides labelled with 
iTRAQ. Then, these were separated by HPLC, using both reverse phase (RP) and strong 
cation exchange (SCX) columns, followed by nanoLC-ESI MS/MS mass spectrometry. Data 
processing identified 1598 proteins, 1539 of which were quantified; 1275 with more than two 
peptides. 24 proteins were found to be differentially expressed in tripleAD compared to the 
other samples (Table 1).  
 
Deregulated proteins identified by iTRAQ. ProteinPilot requires a minimum of 40 counts 
of iTRAQ reporting ion intensities to calculate iTRAQ ratios. Proteins identified with iTRAQ 
tag ion intensities below this threshold were not quantified. In our study, about 90% of the 
identified proteins had iTRAQ ratios (SI Fig. 1A) and of these, about 80% were calculated 
from more than two peptides.  
We tabulated iTRAQ ratios of all proteins using the tripleAD as denominator and 
iTRAQ ratios larger than 1.2 or smaller than 0.82 with a P-value smaller than 0.01 as 
threshold to identify deregulated proteins as listed in Table 1. A protein had to show the same 
deregulation trend in at least two of the three runs to be considered as deregulated. From our 
past experience iTRAQ ratios larger than 1.2 or smaller than 0.82 with a P-value smaller than 
0.01 indicate protein differences of at least 1.5 fold. 
Consistent with transgenic tau expression, the experimental data show that Tau is 
significantly up-regulated in pR5 mice and tripleAD mouse brain compared to wild-type and 
APP/PS2 mice. We performed an over-representation analysis using the Gene Ontology (GO) 
database to perform a functional characterization of the deregulated proteins and established a 
GO map as described (12). This revealed that one third of the proteins have functions in 
mitochondria, specifically complex I and IV (Table 1). In agreement, separation of 
mitochondrial complexes from cortical brain by two-dimensional resolution confirmed a 
similar deregulation of the 49 kDa subunit of complex I and subunits II and IV of complex IV 
(SI Fig. 1B). Therefore, we decided to assess tripleAD compared to pR5 and APP/PS2 mice for 
mitochondrial function. 
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TripleAD mice exhibit strong defects in mitochondrial OXPHOS, complex activities, and 
energy homeostasis. A high-resolution respiratory system has been used to evaluate the 
capacity of the entire oxidative phosphorylation system (OXPHOS) of cerebral mitochondria 
from the four mouse strains (Fig. 1A). We determined flux control ratios to obtain 
information on metabolic states of respiration. The respiratory control ratio (RCR3/4) is an 
indicator of the state of coupling of mitochondria. State 3 is the rate of phosphorylating 
respiration in the presence of exogenous ADP, while state 4 is associated with proton leakage 
across the inner mitochondrial membrane in the absence of ADP. Our data demonstrate a 
pronounced decrease of RCR3/4 in mitochondria from APP/PS2 and tripleAD compared to age-
matched wild-type mice (Fig. 1B). When we examined the ETS/ROX (electron transport 
system/residual oxygen consumption) ratio which yields an index of the maximum oxygen 
consumption capacity relative to the magnitude of residual oxygen consumption, we found 
that it was also decreased in APP/PS2 and tripleAD compared to age-matched wild-type mice 
(Fig. 1C). We have shown previously that respiration of mitochondria from pR5 mice is 
reduced compared to wild-type controls but not until the age of 24 months (4). In contrast, 
 
Accession Name 
Wild-
type vs 
tripleAD 
pR5 vs 
tripleAD  
APP/ 
PS2 vs 
tripleAD 
ANXA5_MOUSE (P48036) Annexin A5 (Annexin V) (Lipocortin V)  1.28   0.63 
ANXA6_MOUSE (P14824) Annexin A6 (Annexin VI) (Lipocortin VI)  1.46 2.2   
ARF3_MOUSE (P61205) ADP-ribosylation factor 3     0.65 
BASP_MOUSE (Q91XV3) 
Brain acid soluble protein 1             
(BASP1 protein)    1.51   
CALM_MOUSE (P62204) Calmodulin (CaM)   0.78 0.65 
COX2_MOUSE (P00405) 
Cytochrome c oxidase subunit 2           
(EC 1.9.3.1)    1.42   
COX41_MOUSE (P19783) 
Cytochrome c oxidase subunit IV  
isoform 1, mitochondrial precursor                      
(EC 1.9.3.1)  1.36 1.47   
COX5A_MOUSE (P12787) 
Cytochrome c oxidase polypeptide Va, 
mitochondrial precursor (EC 1.9.3.1) 1.21 1.43   
COX5B_MOUSE (P19536) 
Cytochrome c oxidase polypeptide Vb, 
mitochondrial precursor (EC 1.9.3.1)   1.33   
CX7A2_MOUSE (P48771) 
Cytochrome c oxidase polypeptide     
VIIa-liver/heart, mitochondrial precursor 
(EC 1.9.3.1)    1.69   
HBA_MOUSE (P01942) Hemoglobin alpha subunit  0.73 0.69   
HBB1_MOUSE (P02088) Hemoglobin beta-1 subunit chain 0.69   0.6 
MBP_MOUSE (P04370) 
Myelin basic protein (MBP) (Myelin A1 
protein) 1.32   1.22 
NDKA_MOUSE (P15532) 
Nucleoside diphosphate kinase A         
(EC 2.7.4.6)      0.56 
NIDM_MOUSE (Q9DCS9) 
NADH-ubiquinone oxidoreductase 
PDSW subunit (EC 1.6.5.3)    1.39 0.66 
NUCM_MOUSE 
(Q91WD5) 
NADH-ubiquinone oxidoreductase 49 
kDa subunit, mitochondrial precursor 
(EC 1.6.5.3)      0.8 
NUIM_MOUSE (Q8K3J1) 
NADH-ubiquinone oxidoreductase 23 
kDa subunit, mitochondrial precursor 
(EC 1.6.5.3)  1.22     
PHB_MOUSE (P67778) 
Prohibitin (B-cell receptor associated 
protein 32) (BAP 32)     0.77 
PPIA_MOUSE (P17742) 
Peptidyl-prolyl cis-trans isomerase A 
(EC 5.2.1.8)      1.4 
S12A2_MOUSE (P55012) 
Solute carrier family 12 member 2 
symporter)   1.49   
SYN2_MOUSE (Q64332) Synapsin-2 (Synapsin II)   1.69   
TAU_MOUSE (P10637) 
Microtubule-associated protein tau 
(Neurofibrillary tangle protein)  0.64   0.6 
THY1_MOUSE (P01831) 
Thy-1 membrane glycoprotein      
precursor  1.4 1.94   
VA0D_MOUSE (P51863) Vacuolar ATP synthase subunit d  1.35 1.71 0.77 
 
 
 
Table 1. Differentially expressed proteins observed by the iTRAQ experiment. Crossbreed mouse samples were 
compared to other types. Deregulated subunits of complex I and complex IV are highlighted in yellow. 
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APP/PS2 mitochondria showed a decrease in OXPHOS compared to wild-type already at the 
age of 8 months (Fig. 1D). At this age, OXPHOS of brain mitochondria from tripleAD mice did 
not differ compared to that of age-matched APP/PS2 mitochondria (Fig. 1E), but it was 
significantly decreased in tripleAD mice at the age of 12 months (Fig. 1F-G). Taken together, 
with increasing age, the global failure of the mitochondrial respiratory capacity deteriorated 
the strongest in mitochondria from tripleAD mice, suggesting a synergistic destructive effect of 
tau and Aβ on mitochondria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. High-resolution respiratory system reveals a heightened defect in the mitochondrial OXPHOS from 
brains of tripleAD mice. Measurement of oxygen (O2) flux and consumption in freshly isolated mitochondria 
from cortical brains of wild-type and age-matched APP/PS2 and tripleAD mice. After detection of endogenous 
respiration (mito), glutamate+malate (g/m) were added to induce state 4 respiration. ADP stimulated state 3 
respiration. After determining coupled respiration, FCCP was added and the maximal respiratory capacity 
measured in the absence of a proton gradient. Cytochrome c (cyt c) demonstrated mitochondrial membrane 
integrity. To inhibit activities of complexes I - III, rotenone (rot) and antimycine A (AA) were added. Complex 
IV activity was stimulated by ascorbate/TMPD (A/T) before terminating mitochondrial respiration by adding 
sodium azide (azide). O2 consumption was normalised to the corresponding citrate synthase (CS) activity. (A) 
Representative diagrams of O2 flux and consumption in mitochondria from 12-months-old wild-type, APP/PS2 
and tripleAD mice in response to titrated substrates and inhibitors of mitochondrial complexes. (B) RCR3/4 
(state3/state4 ratio) representing the mitochondrial coupling state was reduced in 8- and 12-months-old APP/PS2 
and tripleAD mice. (C) ETS/ROX ratio, which yields an index of the maximum oxygen consumption capacity of 
the electron transport system (ETS) relative to the magnitude of residual oxygen consumption (ROX), was 
reduced in 8- and 12-months-old APP/PS2 and tripleAD mice compared with age-matched wild-type 
mitochondria. (D) Two-way ANOVA revealed a significant effect of the transgene on the respiratory rates of 
mitochondria between 8-months-old wild-type and APP/PS2 mice (p<0.001). (E) No difference was observed in 
respiration between 8-months-old APP/PS2 and tripleAD mice. (F) At 12 months of age, respiration differed again 
significantly between wild-type and APP/PS2 (p<0.001) and (G) between APP/PS2 and tripleAD mice (p<0.001). 
A-G: *, p<0.05; **, p<0.01; ***, p<0.001 vs wild-type; ++, p<0.01; +++, p<0.001 versus APP/PS2 (n = 7-12 
animals/group).  
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Next, we used a direct measurement of the specific activity of complex I in freshly 
isolated brain mitochondria, i.e. NADH-ubiquinone oxidoreductase activity measured as 
NADH:DBQ activity that is then normalised to complex I content (NADH:HAR activity). At 
8 months, complex I activity was only decreased in pR5 mice confirming our previous data 
about complex I deficiency in these mice (4) (Fig. 2A). At 12 months of age, all three 
transgenic mouse models exhibited a significant decrease of DBQ/HAR compared to wild-
type mice (Fig. 2A). Interestingly, at the age of 12 months, content of complex I (measured by 
HAR activity) was increased in tripleAD mice suggesting a compensatory up-regulation in 
response to functional deficits of this complex (SI Fig. 3). Similarly, compared to APP/PS2 
mice complex I proteins were found to be up-regulated (Table 1). Activity of citrate synthase 
(CS), a pace making enzyme in the first step of the Krebs cycle, thought to be proportional to 
the content of OXPHOS enzymes (13), was increased in 8-months-old APP/PS2 and tripleAD 
mice. At 12 months, the increase persisted only in cortical mitochondria from tripleAD mice 
suggesting a compensatory incapacity to restore a physiological state specifically in this 
mouse model that exhibits the strongest AD pathology of both plaques and tangles (Fig. 2B).  
At the age of 8 months, APP/PS2 and tripleAD mice showed a significantly decreased 
complex IV activity (CIV/CS ratio) (Fig. 2C). This decrease became more marked at the age 
of 12 months, when the accumulation of defects in the single complexes as well as in the 
entire OXPHOS, respectively, could not be further compensated as shown by a drop in ATP 
levels in cortical brain cells from APP/PS2 and tripleAD mice, with the strongest decrease seen 
in the latter (Fig. 2D). This indicates a general disturbance of cellular energy homeostasis in 
the cortices of these mice. The effect was brain region-specific as no difference in ATP levels 
was observed in cerebellar cells from the same mice (SI Fig. 2). 
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Fig.2. Impaired mitochondrial enzyme activities and decreased ATP levels in cortical brain cells from 
tripleAD mice. (A) Complex I activity (DBQ/HAR ratio) was decreased in 8-months-old pR5 mitochondria. At 12 
months, all three transgenic mouse models presented a decrease in complex I activity. (B) Citrate synthase (CS) 
activity was increased in 8-months-old APP/PS2 and tripleAD mice. At 12 months, the increase persisted only in 
tripleAD mice. (C) Complex IV activity (CIV/CS ratio) was decreased in APP/PS2 and tripleAD mitochondria at 8 
months of age. The decrease became more pronounced at the age of 12 months. (D) ATP levels were reduced in 
12-months-old APP/PS2 and triple mice. A-D:  *, p<0.05; **, p<0.01; ***, p<0.001 versus wild-type; +, p<0.05 
versus pR5 (n = 7-12 animals/group). 
 
 
Aβ and hyperphosphorylated tau cause a decreased mitochondrial membrane potential 
(MMP). Based on our recent in vitro results that cortical brain cells from pR5 mice are 
particularly sensitive to synthetic Aβ insult (14, 15), we determined the mitochondrial 
membrane potential (MMP) that is widely considered as an indicator of mitochondrial 
functionality (16). Basal MMP was significantly and exclusively reduced in cortical cells 
from 8-months-old tripleAD mice. At 12 months, MMP was additionally reduced in cortical 
cells from APP/PS2 mice (Fig. 3A). Again, this effect was brain region-specific as it was not 
observed for the cerebellum (SI Fig. 4A).  
 
Increased mitochondrial failure is accompanied by enhanced reactive oxygen species 
(ROS) production. Superoxide anion levels were enhanced in cortical brain cells of 12 
months-old APP/PS2 mice and markedly increased in those of age-matched tripleAD mice (Fig. 
3B). In addition, cytosolic ROS levels were enhanced in brain cells from APP/PS2 and 
tripleAD mice (Fig. 3C). These differences were only observed at an age of 12, and not 8 
months (SI Fig. 4B and C), suggesting that at the older age, brain mitochondria are not 
capable of compensating their respiratory failure.  
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Fig.3. Reduced MMP and increased ROS levels in cortical brain cells from tripleAD mice. (A) MMP (TMRE 
fluorescence units/mg protein) was reduced in cortical cells from 8-months-old tripleAD mice. At the age of 12 
months, MMP was also reduced in cells from APP/PS2 mice. (B) Levels of superoxide anion radicals (DHE 
fluorescence units/mg protein) and (C) cytosolic ROS (DCF fluorescence units/mg protein) were increased in 
cells from 12-months-old APP/PS2 and tripleAD mice. A-D: *, p<0.05; **, p<0.01; vs wild-type, ++ p<0.01 versus 
pR5 (n = 7-12 animals/group). 
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DISCUSSION 
 
Energy deficiency and mitochondrial dysfunction have been recognized as a 
prominent, early event in AD, but the mechanisms leading to mitochondrial failure are not 
well understood (15, 17-25). Recently, we had shown in vivo that P301L mutant tau was 
capable of inducing mitochondrial dysfunction and increasing levels of ROS in pR5 mice (4). 
We had also found an increased mitochondrial vulnerability of pR5 cortical brain cells 
towards Aβ in vitro (4, 14). However, the relative contribution of tau and Aβ remained 
unclear as did possible synergistic effects. To address these, we investigated brains of pR5, 
APP/PS2 and tripleAD (pR5/APP/PS2) mice, the latter combining Aβ and tau pathologies.  
 
In the present study we could clearly show that with increasing age, both Aβ and tau 
synergistically impair mitochondrial function and energy homeostasis in vivo. At 8 months of 
age, in agreement with previous data (4), complex I activity was only decreased in pR5, but 
not in APP/PS2 and tripleAD mice indicating a tau-specific sensitivity of complex I of 
OXPHOS. In contrast, CS activity, a pace making enzyme of the Krebs cycle, was increased 
in 8-months-old APP/PS2 and tripleAD mice. At this age, a robust cortical pathology of Aβ 
plaques and tau deposits is present (11). Since CS activity seems to be proportional to the 
content of enzymes of OXPHOS (13), the increased activity can be interpreted as 
compensatory mechanism of mitochondria in response to OXPHOS failure, a mechanism 
initiated in tripleAD mice already at the age of 4 months, when Aβ accumulation and abnormal 
tau phosphorylation (such as of epitope T231) become evident (11). Notably, at this early age, 
cortical brain cells from tripleAD mice exhibit already a tendency to reduced MMP suggesting 
that this is a very sensitive indicator of early mitochondrial failure. The decrease in MMP 
(that was not seen in the parental strains) further continued until tripleAD mice reached 8 
months of age emphasizing a synergistic action of Aβ and tau. At 12 months, increased Aβ 
levels per se were able to reduce MMP, since a significant reduction was present also in 
APP/PS2 mice, but the reduction of MMP was more pronounced in tripleAD mice. 
Complex IV activity was decreased in APP/PS2 and triple AD cortices at 8 months of 
age, but not in pR5, confirming related findings that it is mainly the Aβ pathology that affects 
complex IV activity, both in vivo and in vitro (23, 26, 27). In APP/PS2 compared to wild-type 
mice, an impairment of OXPHOS as detected by decreased oxygen consumption was seen at 
this age suggesting an earlier and stronger effect of the Aβ/APP pathway on this vulnerable 
mitochondrial system compared to tau, as oxygen consumption of pR5 mitochondria was 
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reduced, but not until the mice reached 24 months of age (4). Similarly, both flux control 
ratios RCR3/4 and ETS/ROX which measure metabolic states of mitochondrial respiration 
were similarly decreased in APP/PS2 and tripleAD mitochondria indicating an Aβ-induced 
increase of the uncoupling state of these organelles. The data indicate that Aβ affects 
mitochondrial function more extensively and at different levels of respiration and function 
than does tau which only shows an early effect on the activity of a single complex of 
OXPHOS, but evidently increases the vulnerability to Aβ toxicity in vivo. Notably, at 8 
months, no change in cellular energy homeostasis or oxidative stress levels was evident 
suggesting an efficient compensatory machinery within brain cells at this age. 
 
However, as the mice aged, impairment of OXPHOS and mitochondrial enzyme 
activities was aggravated, especially in the presence of both plaques and tangles. Indeed, 
despite compensatory mechanisms – increased complex I content and CS activity – the 
defects of complex I and IV became more marked at 12 months, indicating a failure to restore 
the bioenergetic homeostasis in tripleAD mice as they age. Then, we also observed a difference 
in oxygen consumption between APP/PS2 and tripleAD mice as well as a drop in ATP levels, 
with the strongest decrease found in tripleAD again suggesting a synergistic action of the two 
lesions on mitochondria. These mitochondrial defects were associated with an increase of 
superoxide anion as well as cytosolic ROS levels in 12 month-old APP/PS2 and were most 
pronounced in tripleAD mice suggesting that at this older age detoxifying mechanisms fail to 
balance increased ROS production which in turn might further damage mitochondrial 
OXPHOS.  
 
In agreement with our functional data, iTRAQ MS identified three deregulated 
subunits of complex I in tripleAD mice: NUCM, NUIM, and NIDM. NUCM likely has a 
central role within the catalytic core of mitochondrial complex I (28). Interestingly, NUCM 
and NIDM were up-regulated in tripleAD brain, probably as a compensatory response to the 
functional failure of OXPHOS. These data nicely correspond with the detected increase in 
complex I content (detected by HAR activity). Inversely, NUIM, which is thought to 
participate in the electron transfer and proton pumping activities of complex I, is down-
regulated in tripleAD mice. Together, these findings emphasize that Aβ and tau synergistically 
impair complex I function with aging. On the contrary, changes in the expression of complex 
IV subunits seem to be mainly related to Aβ. Indeed, a down-regulation of several subunits of 
complex IV is essentially seen between pR5 and tripleAD mice, but not between APP/PS2 and 
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tripleAD mice. Furthermore, our findings of a mitochondrial dysfunction in tripleAD mice are 
supported by a significant deregulation of mitochondria-related proteins: Calmodulin, a small, 
ubiquitous Ca2+-binding protein, and its putative target, the transmembrane proteolipid pore of 
the vacuolar or vesicular ATPase (V-ATPase V0) sector subunit a1, with calmodulin 
functioning in an ATPase V(0)-dependent manner at synapses (29). Interestingly, both 
proteins are deregulated in tripleAD mice. 
 
Our results are in line with recent studies associating Aβ and tau with oxidative stress 
(18, 19, 30, 31). Moreover, APP transport was shown to be impaired by elevated tau, 
suggesting a possible link of the two proteins (31, 32). Oligomeric Aβ can attach to tau (33) 
causing a rapid dissociation of tau from microtubules and a collapse of axonal structures 
leading initially to synaptic malfunction and ultimately, neuronal death (34). Interestingly, Aβ 
may not only be located to the cell surface but also directly interact with mitochondria (21) as 
it can be imported into mitochondria via the translocase of the outer membrane (TOM) 
machinery (35). A crucial role for mitochondria in AD is further underpinned by findings 
linking maternal inheritance of mitochondrial DNA to both predisposition of AD and glucose 
hypometabolism (36) that may reflect energy disturbances as found, e.g., in our tripleAD 
model. 
 
Together, our studies highlight the key role of mitochondria in AD pathogenesis, and 
the close inter-relationship of this organelle and the two main pathological features of the 
disease. This was obtained by combinatorial transgenesis, quantitative proteomics and 
functional assays. We show that disturbances in the respiratory and energy system of tripleAD 
mice are due to: (i) a convergence of Aβ and tau on mitochondria, accelerating defects in 
respiratory capacity, and (ii) a main defect in mitochondrial complexes I and IV. Moreover, 
we found (iii) that age-related oxidative stress may exaggerate the dysfunctional energy 
metabolism in a vicious cycle, finally leading to cell death. Our data complement those 
obtained in a second tripleTG mouse model (37, 38). They may contribute to a better 
understanding of these biochemical pathways and assist in the development of antioxidative 
treatments. Importantly, we could reveal defects of mitochondrial respiratory capacity and a 
failure to restore energy homeostasis in mice with plaques and tangles in vivo consolidating 
the idea that a synergistic effect of tau and Aβ augments the pathological deterioration of 
mitochondria. 
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MATERIALS AND METHODS 
 
Mice used for the studies. Four strains of mice were investigated, single-transgenic pR5 (7), 
double-transgenic APP/PS2 (6), a crossbreeding (tripleAD) (11), and non-transgenic wild-type 
littermate controls. For the proteomic analysis, 6 female mice were sacrificed from each strain 
at 10 months of age, and forebrains dissected. For the functional studies, 7-12 female mice 
were sacrificed from each strain at the age of 2, 4, 8, 12 and 16 months in order to identify the 
age when functional changes start, and forebrains dissected (See SI Methods and 
Supplementary Table 1 for details).  
 
Proteomic approach. Crude synaptosomal preparations of forebrains from freshly sacrificed 
mice were obtained for proteomic studies. The proteins were labelled using the iTRAQ 
technique and separated by both reverse phase and strong cation exchange HPLC. Data were 
acquired by NanoLC-ESI MS/MS mass spectrometry and submitted to ProteinPilot for 
processing (See SI Methods for all details). 
 
Cellular analysis. Brain cells were obtained to determine mitochondrial function. The 
membrane potential of the inner mitochondrial membrane was measured using the dye 
tetramethylrhodamine ethyl ester (TMRE) (4). ATP content was determined using a 
bioluminescence photometer (ViaLightTM HT, Cambrex Bio Science) (14). The total amount 
of mitochondria was measured using the cell-permeable mitochondria-selective dye, 
MitoTracker Green FM (4). Finally, levels of ROS were measured using the fluorescent probe 
H2DCF-DA, and levels of superoxide anion radical using DHE (See SI Methods for all 
details). 
 
Studies of isolated mitochondria. Mitochondria were isolated from mouse forebrains to 
investigate mitochondrial OXPHOS and respiratory capacity. Mitochondrial oxygen 
consumption was measured at 37°C using an Oroboros Oxygraph-2k system (4, 22). Several 
mitochondrial enzyme activities (complex I, complex IV and citrate synthase) were examined 
(13, 22) (See SI Methods for details). 
 
Statistical Analysis. Data are represented as means ± S.E.M. For statistical comparison, 
Student’s t-test, One-way ANOVA followed by Tukey’s post hoc test or Two-way ANOVA 
followed by Bonferroni post tests were used. Only p values less than 0.05 were considered as 
statistically significant.  
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SUPPLEMENTARY INFORMATION 
 
SUPPLEMENTARY METHODS 
 
Animals used for proteomic analysis. Four strains of mice were used in this analysis, single-
transgenic pR5 (1, 2), double-transgenic APP/PS2 (3), a crossbreeding of the two strains 
(tripleAD) (4), and non-transgenic wild-type littermate controls. From each strain, 6 female 
mice were sacrificed at the age of 10 months, and the forebrain dissected. From each forebrain 
we obtained a ‘crude synaptosomal’ (vesicular) fraction, followed by lysis and determination 
of protein content using the DC Protein Assay (BioRad #500-0116). For iTRAQ processing 
and labelling (see below), 33µg were obtained from three samples and mixed before analysis 
to reduce the impact of individual outliers. A mix from animals 1-3 (group 1) of each strain 
was used in the first run and of animals 4-6 (group 2) in the second. Three animals each from 
groups 1 and 2 were randomly chosen for the third run (Supplementary Table 1). 
 
Animals used for analysis of mitochondrial function. Four strains of mice were used: pR5, 
APP/PS2, tripleAD, and non-transgenic wild-type littermate controls. From each strain, 7-12 
female mice were sacrificed at the age of 2, 4, 8, 12 and 16 months in order to identify the age 
when functional changes start, and forebrains dissected.  
 
Crude vesicular extraction and lysis. To prepare a crude vesicular extract from freshly 
sacrificed mice, forebrains were separated from brainstem and cerebellum. Forebrains were 
transferred into 5 ml pre-chilled preparation buffer (0.32 M Sucrose, 1 mM NaHCO3, 1 mM 
MgCl2, 0.5 mM CaCl2) containing protease inhibitors (Complete, EDTA-free, Roche 
#11873580001). They were slowly and gently homogenised in a douncer, with 12 up and 
down strokes at 700 rpm. The lysate was then spun in a centrifuge at 1,400 g for 10 minutes at 
4°C. The supernatant (S1) was saved and the pellet resuspended in 2 ml preparation buffer 
containing protease inhibitors. The suspension was homogenised further with 3 slow and 
gentle up and down strokes at 700 rpm and then spun in a centrifuge at 720 g for 10 minutes 
at 4°C. The pellet was discarded and the supernatant (S2) combined with supernatant S1. The 
lysate was then spun again in a centrifuge at 720 g for 10 minutes at 4°C and the pellet was 
discarded. Crude vesicles including synaptosomes were then pelleted at 13,800 g for 10 
minutes at 4°C. 
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 The crude synaptosomal preparation was resuspended in 500 µl RIPA buffer (50 mM 
Tris-HCl pH7.5, 1% (v/v) Triton X-100, 0.1 % (v/v) SDS, 15 mM sodium deoxycholate, 375 
mM NaCl, 10 mM EGTA) containing Complete, EDTA-free protease inhibitors. Samples 
were homogenised by passing through a Terumo syringe needle (22Gx1 ½”) and 
subsequently incubated on ice for one hour. Lysates were then further passed through a 
Terumo Insulin syringe (29Gx ½”) and centrifuged at 22,000 g for 10 minutes at 4°C. The 
pellet was discarded and the supernatant used for further analysis. 
 
Protein digestion and iTRAQ labelling. Preparation and labelling was conducted according 
to the iTRAQ manual (Applied Biosystems). In short, 100 µg of protein was acetone-
precipitated and resuspended in 20 µl of dissolution buffer (0.5 M triethylammonium 
bicarbonate) containing 0.1 % (v/v) SDS. The sample was then reduced by adding TCEP (tris-
(2-carboxyethyl) phosphine) to a concentration of 50 mM and incubated at 60°C for 1 hour. 
Subsequently, the sample was treated with 200 mM MMTS (methyl methanethiosulfate) for 
alkylation/cysteine blocking for 10 minutes at room temperature. The protein sample was then 
treated with 4 µg trypsin (Trypsin Gold, Promega) per 100 µg protein at 37°C for 16 to 24 
hour. Labelling of the samples with iTRAQ labels was done at room temperature for one 
hour. Supplementary Table 1 shows the iTRAQ labels and the corresponding samples. In each 
iTRAQ run, the different samples were mixed after labelling and dried in SpeedyVac. The 
dried samples were then stored at -20ºC before 2-dimensional HPLC peptide separation and 
data acquisition. 
 
First dimensional HPLC for peptide fractionation. To investigate the effect of the first 
dimensional HPLC peptide separation, we used both reverse phase (RP) and strong cation 
exchange (SCX) to fractionate peptides.  RP HPLC was used for Run1; SCX HPLC was used 
for Run2; RP HPLC and SCX HPLC were both used in parallel for Run3 and this run 
identified most proteins. The collected fractions from the first dimensional HPLC were dried 
in SpeedyVac and then stored at -20°C before nanoLC-ESI MS/MS data acquisition. 
SCX HPLC: An Agilent 1100 quaternary HPLC pump with a PolyLC PolySulfoethyl 
A (200mm x 2.1mm x 5µm, 200A) column was used for strong cation exchange 
chromatography sample clean up and fractionation. Buffer A was 5 mM Phosphate 25% 
acetonitrile, pH 2.7 and buffer B was 5 mM phosphate, 350 mM KCL, 25% acetonitrile, pH 
2.7. The dried iTRAQ-labelled sample was resuspended with loading buffer (buffer A) and 
loaded onto the SCX column. The flow through was discarded as this contained interfering 
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chemicals for the second dimensional nanoLC and mass spectrometry. To elute peptides, 
buffer B gradient was increased from 10% to 45% in 70 minutes at a flow rate of 300 µl/min. 
25 fractions were collected beginning from the start of the gradient.  
RP HPLC: The sample was first cleaned up using Strong Anion Exchange resin 
(BioRad Macro-prep High Q Support) to remove neutral or negatively charged chemicals that 
would interfere with reverse phase HPLC separation and mass spectrometry data acquisition. 
The reverse phase HPLC fractionation used column Phenomenex Jupiter 5u C4 300A 
150x2.00mm. Buffer A was 0.1% TFA in MilliQ water, Buffer B was 0.085% TFA in 
acetonitrile. After 10 minutes sample loading and desalting, Buffer B gradient was increased 
from 5% to 40% in 25 minutes and then increased to 90% in 5 minutes to elute peptides. The 
fractions were collected at one minute intervals.  
 
NanoLC-ESI MS/MS mass spectrometry. The Agilent 1100 nanoLC system (Agilent) and 
the QStar XL MS/MS system (Applied Biosystems) were used for nanoLC-electrospray 
MS/MS. The peptide fractions from first dimensional HPLC were resuspended with 
loading/desalting solution (0.1% trifluoroacetic acid, 2% acetonitrile, 97.9% water). The 
resuspended sample was loaded onto a peptide Captrap column (Michrom Bioresources) and 
desalted with the desalting solution at 10 µl per minute for 13 minutes. After desalting, the 
trap was switched online with a 150 µm x 10 cm C18 3µm 300A ProteCol column (SGE). 
Buffer solution A was 99.9% water/0.1% formic acid, buffer solution B was 90% 
acetonitrile/9.9% water/0.1% formic acid.  The buffer B concentration was increased from 5% 
to 90% in 120 minutes in three linear gradient steps to elute peptides. The RP nanoLC eluent 
was subjected to positive ion nanoflow ESI analysis in an information-dependant acquisition 
mode (IDA). In the IDA mode, a TOF-MS survey scan was acquired (m/z 380-1600, 0.5 
second), with the three most intense multiply charged ions (counts >50) in the survey scan 
sequentially subjected to MS/MS analysis. MS/MS spectra were accumulated for 2 seconds in 
the mass range m/z 100-1600 with a modified Enhance All Q2 transition setting favouring 
low mass ions so that the reporting iTRAQ tag ion (114, 115, 116 and 117 Da) intensities 
were enhanced for quantification. After peptide elution, the nanoLC column was cleaned with 
100% buffer B for 15 minutes and then equilibrated with buffer A for 30 minutes before the 
next sample injection.  
 
Database processing. The experimental nanoLC-ESI MS/MS data were submitted to 
ProteinPilot (Applied Biosystems, version 1.0) for data processing. The Paragon method was 
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used in thorough ID search effort with Biological modifications selected in ID Focus. The 
software correction factors provided in the iTRAQ kit were entered in the iTRAQ Isotope 
Correction Factors table. The detected protein threshold (unused ProtScore) was set as larger 
than 1.3 (better than 95% confidence). The database used was uniprot_sprot20051220 with 
Mus musculus specified as the searched species.  
After ProteinPilot data processing, the protein summary which listed the identified 
proteins and their iTRAQ ratios was exported as tab delimited text file. To compare the runs, 
all identified proteins from all runs were aligned using an excel macro. To highlight 
differentially expressed proteins, iTRAQ ratios larger than 1.2 or smaller than 0.82 and a P-
value smaller than 0.05 were used as threshold.     
 
BN-Page and Tricine-SDS-Page. Sample preparation, Blue Native (BN) electrophoresis, 2D 
Tricine-SDS-PAGE were performed as described (5). Per lane, the n-dodecyl-ß-D-maltoside 
(7 g/ g mitochondrial protein) solubilized fraction of ~10 mg protein from isolated mouse 
brain mitochondria was separated in the first dimension (acrylamide gradient 4-13 %, sample 
gel 3.5%). The native lanes were cut and used for 2D SDS PAGE (16% acrylamide) to 
separate the subunits of the respiratory chain complexes. Finally the gels were visualized by 
silver staining as described (6). 
 
Brain tissue preparation for mitochondrial analysis. Cellular preparations were obtained to 
determine the mitochondrial membrane potential (MMP) and mitochondria, to determine 
respiration rates as described previously (7, 8). For that, mice were sacrificed by decapitation 
and brains quickly dissected on ice. The cerebellum and one cortical hemisphere (the other 
hemisphere was directly used for preparation of isolated mitochondria for mitochondrial 
respiration and complex activities) were separately minced into 1 ml of medium I (138 mM 
NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4, 0.22 mM K2PO4, 5.5 mM glucose, 58.4 mM sucrose, 
pH 7.35) with a scalpel and further dissociated by trituration through a nylon mesh (pore 
diameter 1 mm) with a pasteur pipette. The resulting suspension, which contained both 
neuronal (about 72%) and glial cells (about 26%), was filtered by gravity through a fresh 
nylon mesh with a pore diameter of 102 µm, and the dissociated cell aggregates were washed 
twice with medium II (110 mM NaCl, 5.3 mM KCl, 1.8 mM CaCl2*H2O, 1 mM MgCl2*6 
H2O, 25 mM glucose, 70 mM sucrose, 20 mM HEPES, pH 7.4) by centrifugation (400 x g for 
3 min at 4°C). 100 µl of the suspension were used for protein determination. After 
centrifugation, cells were resuspended in 3 ml DMEM, and then aliquots of 100 µl were 
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distributed per well in a 48 well plate for measurement of the mitochondrial membrane 
potential. The preparations of cerebellar and cortical cells from transgenic mice and WT 
littermate controls (cross-over design) were made within 2 hours under the same conditions 
and in parallel and maintained at 37°C in a humidified atmosphere of 5% CO2/95% air. 
Viability was found to be > 90% using the MTT assay and Trypan blue stain exclusion test. 
Data are expressed as fluorescence units per mg/ml protein. 
 
Determination of the mitochondrial membrane potential MMP. The membrane potential 
of the inner mitochondrial membrane was measured using the dye tetramethylrhodamine ethyl 
ester (TMRE, Molecular Probes, Leiden, Netherlands) added to the cell culture medium at a 
final concentration of 0.4 µM for 15 min. Cells were washed twice with HBSS (Hank’s 
Balanced Salt Solution, Sigma, Germany), and fluorescence was determined with a Victor2 
multiplate reader (Perkin Elmer, Rodgau-Jügesheim, Germany) at 535 nm/590 nm (Ex/Em) 
(7). 
 
ATP levels. The ATP content of dissociated cells was determined with a bioluminescence 
photometer (ViaLightTM HT, Cambrex Bio Science) according to the instruction of the 
manufacturer. The enzyme luciferase which catalyzes the formation of light from ATP and 
luciferin is utilized. Dissociated brain cells were lysed before the addition of the reagent. The 
emitted light is linearly related to the ATP concentration and is measured using a luminometer 
(7). 
 
Amount of mitochondria. The total amount of mitochondria was measured using the cell-
permeable mitochondria-selective dye, MitoTracker Green FM (100 nM, 15 min) (7). This 
probe can accumulate in active mitochondria and then react with accessible thiol groups of 
proteins and peptides to form fluorescent aldehydic-fixable conjugates. Fluorescence was 
determined using a Victor2 multiplate reader (PerkinElmer Life Sciences) at 490 nm 
(excitation)/516 nm (emission). 
 
ROS levels. The levels of ROS were measured using the fluorescent probe H2DCF-DA and 
the levels of superoxide anion radical were measured using DHE (9). The brain cells were 
loaded for 15 min with 10 µM H2DCF-DA or for 60 minutes with 10 µM DHE. After 
washing twice with Hank’s balanced salt solution, the formation of the fluorescent product 
dichlorofluorescein was detected using the Victor2 multiplate reader (PerkinElmer Life 
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Sciences) at 485 nm (excitation)/535 nm (emission). DHE, which is oxidized to the 
fluorescent ethidium cation by O2.- was detected using the Victor2 multiplate reader at 490 
nm (excitation)/590 nm (emission). 
 
Preparation of isolated mitochondria. Mitochondria were isolated from mouse brains as 
described previously (7). Briefly, mice were sacrificed by decapitation, and one brain 
hemisphere was rapidly dissected on ice and washed in an ice-cold buffer (210mM mannitol, 
70mM sucrose, 10mM HEPES, 1mM EDTA, 0.45% bovine serum albumin, 0.5mM 
dithiothreitol, and Complete protease inhibitor mixture tablets (Roche Diagnostics)). After 
removing the cerebellum, the tissue sample was homogenized in 2ml of buffer with a glass 
homogenizer (10–15 strokes, 400 rpm), and the resulting homogenate was centrifuged at 
1,400g for 7min at 4°C to remove nuclei and tissue particles. The low-speed centrifugation 
step was repeated once with the supernatant. Then, the supernatant fraction was centrifuged at 
10,000 g for 5 min at 4°C to pellet mitochondria. The resulting pellet was resuspended in 1ml 
of ice-cold buffer and centrifuged again at 1,400g for 3 min at 4°C. Finally, the mitochondria-
enriched supernatant was centrifuged at 10,000g for 5 min at 4°C to obtain a mitochondrial 
fraction. This fraction was resuspended in 100µl of ice-cold buffer and stored at 4°C until use, 
followed by determination of protein content (7). 
 
Mitochondrial respiration. Mitochondrial oxygen consumption was measured at 37°C using 
an Oroboros Oxygraph-2k system. Isolated mitochondria (0.5mg) were added to 2ml of a 
mitochondrial respiration medium containing 65mM sucrose, 10mM potassium phosphate, 
10mM Tris-HCl, 10mM MgSO4, and 2mM EDTA (pH 7.0) (7). To measure the state 4 of the 
complex I, 10mM glutamate and 2mM malate were added. Then, 2mM ADP was added to 
measure state 3 respiration. After determining coupled respiration, 0.05µM FCCP (Carbonyl 
cyanide p-(trifluoro-methoxy) phenyl-hydrazone) was added and respiration was measured in 
the absence of a proton gradient. To check the integrity of the mitochondrial membrane 10µM 
cytochrome c was added. In order to inhibit complex I and III activities 0.5µM rotenone and 
2.5µM antimycin A, respectively were added. Then, 2mM ascorbate and 0.5mM TMPD were 
added and respiration was measured. Finally, 10mM sodium azide was added to inhibit 
complex IV activity (10). Mitochondria from transgenic and control mice were measured in 
parallel pairs using the same conditions (crossover design). 
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Activity of complex I. 100µg of isolated mitochondria were solubilized in n-dodecyl β-D-
maltoside (0.1mg). NADH:hexaammineruthenium(III)-chloride (HAR) activity was measured 
at 30 °C in a buffer containing 2mM Na+/MOPS, 50mM NaCl, and 2mM KCN, pH 7.2, using 
2mM HAR and 200µM NADH as substrates to estimate the complex I content. To determine 
NADH-ubiquinone oxidoreductase activity, 100µM n-decylubiquinone (DBQ) and 100µM 
NADH were used as substrates and 5µM rotenone as inhibitor, as described previously (7). 
Oxidation rates of NADH were recorded with a Shimadzu Multi Spec-1501 diode array 
spectrophotometer (ε340-400nm = 6.1 mM-1.cm-1). Complex I activity was normalized to the 
complex I content of the mitochondrial preparation and is given as DBQ/HAR ratio.  
 
Activity of complex IV. Cytochrome c oxidase activity was determined in intact isolated 
mitochondria (50µg) using the Cytochrome c Oxidase Assay Kit. The colorimetric assay is 
based on the observation that a decrease in absorbance at 550 nm of ferrocytochrome c is 
caused by its oxidation to ferricytochrome c by cytochrome c oxidase. The Cytochrome c 
Oxidase Assay was performed as described previously (7). Activity was normalized to the 
corresponding citrate synthase. 
 
Activity of citrate synthase. The reduction of 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) by 
citrate synthase at 412 nm (extinction coefficient of 13.6 mM-1.cm-1) was followed in a 
coupled reaction with coenzymeA and oxaloacetate as described previously (11). Briefly, a 
reaction mixture of 0.2M Tris-HCl, pH 8.0, 0.1mM acetyl-coenzymeA, 0.1mM DTNB, n-
dodecyl-β-D-maltoside (20%) and 10µg of mitochondrial protein was incubated at 30°C for 5 
min. The reaction was initiated by the addition of 0.5mM oxaloacetate, and the absorbance 
change was monitored for 5min with a Shimadzu Multi-Spec-1501 diode array 
spectrophotometer (10). 
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SI Fig.1. Quantitative proteomic analyses and separation of dodecylmaltoside-solubilized mitochondrial 
complexes from mouse brain. (A) Total of proteins identified and quantified in each run and proteins identified 
in Run3 (Suppl. Table 1) by combined strong cation exchange (SCX) HPLC and reverse phase (RP) HPLC. (B) 
Solubilized brain mitochondrial complexes (I–III and V) from 12 months old mice with different genetic 
background (pR5; APP/PS; tripleAD) were separated on a linear 4-13% acrylamide gradient gel by BN-PAGE 
(not shown) and subsequently the individual subunits of the native complexes were separated by tricine-SDS-
PAGE using a 16% T, 3% C gel type as detailed under Materials and Methods. Proteins were visualized by 
silver staining. The position of the 49 kDA subunit of complex I and the positions of the complex IV subunits II 
and IV are indicated. 
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SI Fig.2. No drop of ATP synthesis in cerebellar cells. Decrease of ATP levels is brain region specific since 
no difference in ATP levels was observed between cerebellar cells from the different mouse models (A) at the 
age of 8 and (B) 12 months. Values represent the means ± S.E. from n= 7-12 animals/group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SI Fig.3. Increase of complex I content in cortical brain from tripleAD mice. The complex I content (HAR 
activity) significantly increased in the mitochondria of tripleAD mice (B) at the age of 12 months (*, p<0.05 vs wt, 
Student t-test). Values represent the means ± S.E. from n= 7-12 animals/group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SI Fig.4. Unchanged MMP and levels of ROS in cerebellar cells at 8 months of age. (A) The decrease of the 
basal mitochondrial membrane potential is brain-region specific, since no difference was observed in cells from 
cerebellum. (B) Superoxide anions levels determined by DHE oxidation and (C) cytosolic ROS levels from 
cortical cells measured after incubation with DCF did not increase at 8 months. Values represent the means ± 
S.E. from n= 7-12 animals/group. 
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SUPPLEMENTARY TABLE 
 
 
 
 
 
 
 
 
 
iTRAQ 
Runs 
2DLC 114 115 116 117 
Run1  RP-RP A (1, 2, 3) B (1, 2, 3) C (1, 2, 3) D (1, 2, 3) 
Run2 SCX-RP A (4, 5, 6) B (4, 5, 6) C (4, 5, 6) D (4, 5, 6) 
Run3 RP-RP A (1, 2, 5) B (2, 3, 4) C (3, 5, 6) D (2, 5, 6) 
 
 
Supplementary Table 1. iTRAQ experiment runs and the mouse sample labelling. A: wild-
type; B: pR5; C: APP/PS2; D: tripleAD 
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ABSTRACT 
 
Aims: Evidence suggests that amyloid-beta (Aβ) protein is a key factor in the pathogenesis of 
Alzheimer’s disease (AD) and it has been recently proposed that mitochondria are involved in 
the biochemical pathway by which Aβ can lead to neuronal dysfunction. Here we investigated 
the specific effects of Aβ on mitochondrial function under physiological conditions. 
Methods: Mitochondrial respiratory functions and energy metabolism were analyzed in 
control and in human wild-type amyloid precursor protein (APP) stably-transfected human 
neuroblastoma cells (SH-SY5Y). Mitochondrial respiratory capacity of mitochondrial 
electron transport chain (ETC) in vital cells was measured with a high-resolution respirometry 
system (Oxygraph-2k). In addition, we determined the individual activities of mitochondrial 
complexes I-IV that compose ETC and ATP cellular levels.  
Results: While activities of complexes I and II did not change between cell types, complex IV 
activity was significantly reduced in APP cells. In contrast, activity of complex III was 
significantly enhanced in APP cells, as compensatory response in order to balance the defect 
of complex IV. However, this compensatory mechanism could not prevent the strong 
impairment of total respiration in vital APP cells. As a result, the respiratory control ratio 
(state3/state4) together with ATP production decreased in the APP cells in comparison to 
control cells. 
Conclusions: Chronic exposure to soluble Aβ protein may result in an impairment of energy 
homeostasis due to a decreased respiratory capacity of mitochondrial electron transport chain 
which, in turn, may accelerate neurons demise. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is the most frequent form of dementia among elderly 
individuals and is characterized by neuropathological hallmarks of extracellular amyloid 
plaques and intracellular neurofibrillary tangles in the brain of AD patients. Extensive 
evidences suggest that amyloid-beta (Aβ) protein, which is derived from its precursor protein 
APP, plays a pivotal role in the pathogenesis of AD. In addition, mitochondrial dysfunction 
and energy metabolism deficiencies have been recognized as earliest events in AD (Chagnon 
et al. 1995) and have been correlated with impairments of cognitive abilities in this clinical 
scenario (Blass 2003). The most consistent defect in mitochondrial electron transport chain 
enzymes in AD is the deficiency in cytochrome c oxidase (complex IV) activity in post-
mortem brain tissues, as well as in other tissues, such as platelets from AD patients and AD 
cybrid cells (Cardoso et al. 2004a; Cardoso et al. 2004b). Although, the specific mechanisms 
leading to mitochondrial failure in AD still remain unknown, a substantial body of evidence 
indicates that Aβ promotes neuronal degeneration and death by enhancing neurons 
vulnerability to increases in levels of oxidative stress and impairments in cellular energy 
metabolism (Gibson and Huang 2002; Mattson and Liu 2002). Interestingly, enzyme activities 
in mitochondrial respiratory chain and citric acid cycle, which are reduced in AD, can be 
inhibited by Aβ in vitro. Furthermore, several findings have demonstrated Aβ-induced 
mitochondrial damage, e.g. Aβ inhibited cytochrome c oxidase (COX) activity, in isolated 
brain mitochondria (Canevari et al. 1999; Parker et al. 1994) However, results on how 
mitochondrial respiratory chain complexes and complex IV are affected by Aβ are rather 
inconsistent (Casley et al. 2002b; Cassarino and Bennett 1999; Swerdlow and Kish 2002). It 
has been recently proposed that toxic species of Aβ that intervene in molecular and 
biochemical abnormalities in AD may be intracellular oligomeric forms, instead of 
extracellular, insoluble deposits. According to this hypothesis, mitochondria could intervene 
in the mechanism by which intracellular Aβ triggers synaptic failure and neurodegeneration 
(Eckert et al. 2008). This idea is supported by in vivo evidence of Aβ accumulation within 
mitochondria in brain tissues of AD patients (Fernandez-Vizarra et al. 2004; Lustbader et al. 
2004) and mitochondrial structural abnormalities (Hirai et al. 2001). Taken together, these 
data indicate that mitochondrial dysfunction can play a major role in AD pathophysiology 
(Eckert et al. 2003; Leuner et al. 2007; Rhein and Eckert 2007). 
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To unravel the direct impact of Aβ on mitochondrial respiratory functions, we 
established a new high resolution respiratory protocol to investigate the respiratory capacity 
of mitochondrial electron transport chain (ETC) under physiological conditions in control and 
in wild-type APP stably transfected human neuroblastoma cells (SH-SY5Y). By means of 
stably transfected APP SH-SY5Y cells, which represent a neuronal cell line of human origin 
widely used in studies testing the effect of Aβ in vitro, we circumvent the artificial 
experimental design of most of the other studies, where isolated mitochondria were treated 
with high concentrations of Aβ in the micromolar range (5-50µM). In addition, we determined 
the activities of mitochondrial complexes I-IV composing ETC, as well as the ATP levels. 
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RESULTS 
 
APP expression and Aß levels of APP transfected SH-SY5Y cells. In our cell model, the 
overexpression of human wild-type APP lead to a significantly increased Aß secretion, as 
compared to control cells with the empty vector. The APP expression of APPwt cells was 
substantially increased in comparison to control cells (Fig.1b,d) confirming previous findings 
(Scheuermann et al. 2001). The strong expression of APP was not correlated with a change of 
the general morphological aspect of APP cells compared to control cells (Fig.1a). APP cells 
secreted Aß levels within pg/mL range, reflecting the physiological situation in vivo during 
cellular metabolism (Fig.1c). Using the APP SH-SY5Y cell line allows us to study effects of 
chronic stress of soluble forms Aß protein on cells and mitochondria, respectively, as it may 
occur in the brains of AD patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Human APP and secreted Aβ1-40 levels of SY5Y cells. a) Morphological analysis of native and 
transfected SH-SY5Y cells showed neuroblast-like morphology with differentiated perikaria (arrows) and 
occasional short neurites (arrowheads). Transfection of SH-SY5Y cells with cDNAs (pCEP4 vector) containg 
the vector alone or containing the entire coding region of human APP (APP695) did not significantly change the 
general morphological aspect of the cells. Scale bars: 50µm b) Human APP expression levels of SH-SY5Y cells 
detected by Western Blotting using W02 antibody indicating strong expression of APP in APP transfected cells 
compared to control cells. c) Cell culture supernatants of 5 x 106 SH-SY5Y cells (APPwt, Co) were collected 
and assayed for Aβ1-40 by ELISA. Aβ1-40 levels were significantly enhanced in APP cells compared to control 
cells (***p<0.001, n=6, Student’s t-test). d) Human APP detected by immunochemistry using a monoclonal anti-
APP antibody indicating stronger presence of APP in the APP cells compared to the endogenous APP expression 
in control cells. 
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Amyloid beta leads to mitochondrial respiratory defects. To investigate mitochondrial 
capacity and function of mitochondria in both control and APP cells, we initially focused on 
the activity of the citrate synthase (CS) in both cell types, which was similar in control and 
APP cells (Fig.2a). Given the direct inhibitory effect of extracellular Aß on complex I (10% 
inhibition) (Aleardi et al., 2005), we conducted direct measurements of the complex I activity. 
NADH-ubiquinone oxidoreductase (NADH:DBQ) activity in the mitochondria APP cells did 
not alter, the same occurring for NADH:HAR activity, indicating that the complex I content 
was similar in both cell types. APP mitochondria did not exhibit any loss in complex I 
activity, as indicated by normalization of complex I activity with complex I content expressed 
as DBQ/HAR ratio (Fig. 2b). After normalization of complex I activity with the content of 
mitochondria, complex I / CS ratio did not modify between controls and APP cells (Fig.2c). 
Moreover, activity of respiratory chain complexes II, III and IV were also normalized to the 
corresponding CS activity. Accodingly, we found an unchanged complex II (Fig.2d), although 
there was a significantly up-regulated activity of complex III in APP cells compared to 
control cells (Fig.2e). Similarly we observed a significantly reduced cytochrome c oxidase 
activity between control and APP mitochondria (Fig. 2f), which is consistent with reduced 
complex IV activity in platelets from AD patients (Cardoso et al. 2004a) and the direct 
interaction of Aß with mitochondrial membranes, which results in the inhibition of complex 
IV in vivo (Canevari et al. 1999; Hauptmann et al. 2008). 
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Fig.2 Mitochondrial enzymes activities in control and APP cells. a) Unaltered citrate synthase activity 
between control and APP cells. b) complex I activity (DBQ activity) normalized to the complex I content 
(HAR activity) of the mitochondrial preparation is shown as DBQ/HAR ratio. Complex I activity is unaltered. 
c) unaltered complex I / CS ratio. d) unaltered complex II / CS ratio. e) complex III / CS ratio was significantly 
increased in the APP cells (***, p<0.001 versus control cells, Student’s t test). f) Complex IV / CS ratio was 
significantly decreased in the APP cells (**, p<0.01 versus control cells, Student’s t test). All values represent 
the means ± S.E. from n= 4-6 independent experiments. 
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In order to evaluate the functionality of the respiratory chain, we determined the 
physiological cell respiration in vital control and APP cells (Fig.3). We used the NADH 
generating substrates pyruvate and malate to determine state 4 of respiration (Fig. 3). State 3 
respiration measures the capacity of the mitochondria to metabolize oxygen and the selected 
substrate in the presence of a defined amount of ADP, which is a substrate for the ATP 
synthase (complex V). State 4 respiration represents a “basal-coupled” rate of respiratory 
chain activity and reflects activities of respiratory chain complexes and proton leakage across 
the inner mitochondrial membrane. We observed a significantly reduced state 3 and state 4 
respirations in the APP cells (Fig. 3c). The addition of another substrate of complex I, 
glutamate was not able to further increase cellular respiration driven by complex I in both cell 
types. Afterwards, succinate was added as a substrate for complex II. In control cells, addition 
of succinate substantially increase total cell respiration, while in APP cells only a minor 
increase was observed (Fig.3a). In addition, after uncoupling with FCCP, the respiratory rate 
increased in the absence of a proton gradient, which indicates the maximum capacity of 
electron transport chain. This maximum capacity was significantly enhanced in the control 
cells in relation to the APP cells (Fig.3a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 High-resolution respirometry revealed a reduction of oxygen consumption in APP cells. 
Representative diagrams of measurement of oxygen (O2) consumption in control cells a) and in APP cells b) 
demonstrating a decrease in the total O2 concentration with time . O2 flux and consumption by vital cells was 
measured after addition of different agents: pyruvate/glutamate (pyr/glu), digitonin (dig), ADP, glutamate (glu), 
succinate (suc), cytochrome c (cyt c), FCCP, rotenone (rot), antimycine A (AA). C) O2 consumption in control 
and APP cells. Two-way ANOVA revealed a significant difference between the cellular respiration of the two 
cell types (p<0.001). The respiratory rates of mitochondria were significantly reduced in APP cells. Values 
represent the means ± S.E. from n= 5 assays (cell type). 
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The respiratory control ratio (RCR) revealed a significant effect of Aβ on the coupling 
of mitochondrial respiration, indicating that the relative efficiency of metabolic coupling of 
electron chain complexes is impaired under conditions of chronic stress evoked by soluble 
forms of Aß in our APP cell model (Fig. 4a). ATP levels were significantly reduced in APP 
cells (Fig. 4b). Taken together, these results suggest that soluble species of Aß exhibit an 
initial defect in mitochondrial function with reduced complex IV activity that is translated 
into a mitochondrial respiration deficiency with diminished ATP synthesis, which cannot be 
compensated by an increased activity of complex III. 
 
 
 
 
 
 
 
Fig.4 Reduced respiratory control ratio (state3/state4) (RCR) and impaired ATP synthesis in APP cells. a) 
Significantly reduced RCR in APP cells (***, p< 0.001 versus control cells, Student’s t test), indicating an 
impaired efficiency of electron transport. Values represent means +/- S.E. from n=5. b, in accordance, ATP 
levels are significantly reduced in APP cells (*, p< 0.05 versus control cells, Student’s t test).Values represent 
means ± S.E. from n=5 (measurements of control and APP cells were performed in parallel). 
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DISCUSSION 
 
A priori our findings support a toxic role of Aβ in respiration. Although the specific 
pathways that lead to energy deprivation in AD remain unclear, there is evidence in favour of 
Aβ- induction of cell loss and synaptic failure by energy deprivation and oxidative stress 
(Gibson and Huang 2002; Mattson and Liu 2002). Recently, the focus on toxic species of Aβ 
has switched from its extracellular and fibrillar forms to its soluble species, e.g. oligomers, 
that can be detected ntracellularly and may represent the primary toxic Aβ correlate 
(Fernandez-Vizarra et al. 2004; Lustbader et al. 2004). Accoding to this novel hypothesis, 
mitochondrial dysfunction may play a crucial role in the biochemical pathway, by which Aβ 
can lead to neuronal dysfunction in AD (Eckert et al. 2008). 
 
To unravel the effects of soluble species of Aβ on the mitochondrial respiratory 
capacity under physiological conditions, we established for the first time a high resolution 
respiratory protocol to perform whole cell recording of total cellular respiration in control and 
with wild-type APP stably transfected human neuroblastoma cells (SH-SY5Y). We observed 
an impairment of oxygen consumption rate and a decrease of respiratory control ratio 
(state3/state4) in the APP that might be induced by the chronic over expression of Aβ within 
the low nanomolar range. This defect of the whole mitochondrial respiratory chain may be 
explained by the accumulated dysfunctions of one or several mitochondrial chain complexes. 
To test this hypothesis, we measured individual activities of mitochondrial complexes I-IV as 
well as the ATP levels. Our results clearly show a decrease in complex IV activity in the APP 
cells, which is in accordance to previous findings (Cardoso et al. 2004a; Caspersen et al. 
2005; Hauptmann et al. 2008). Interestingly, the activity of the complex III significantly 
increased, most probably as a compensatory mechanism in response to the toxic effect of Aβ 
on complex IV. Nevertheless, this compensatory response could not entirely balance or avoid 
the impairment of cellular respiration. This finding is in contrast to Caspersen et al. (2005). 
Accordingly, a decrease of complex III activity was revealed, together with a decrease of 
complex IV activity in brain tissues from APP transgenic mice at the age of 12 months. It is 
likely that in our cell model, we were able to detect a premature intervention mechanism in 
response to soluble forms of Aβ as a compensatory increase of complex III activity, whereas 
the strong Aβ load might have lead to a breakdown of that response thus decreasing complex 
III activity. Moreover, we could show that complexes I and II were not affected by Aβ, which 
is in accordance with findings on APP transgenic mice (Caspersen et al. 2005; Hauptmann et 
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al. 2008). However, it contrasts to in vitro findings on isolated mitochondria, which were 
acutely treated with rather high concentrations of aggregated and fibrillar forms of Aβ (5-
50µM), which in turn can induce defects in nearly all complexes (Aleardi et al. 2005; Casley 
et al. 2002a; Casley et al. 2002b). Thus, nearly all other studies used synthetic Aß peptides in 
the micromolar range, many orders of magnitude over physiological levels, and cells or even 
isolated mitochondria were exposed only to synthetic Aß fragments. By contrast, our 
neuroblastoma cell model represents a very valuable approach to investigate AD-specific cell 
death pathways by studying Aß levels within the picomolar range. This cell model attempts to 
mimic physiological conditions studying chronic effects of rather low concentrations of Aß 
that are relevant for AD patients. The fact that the mitochondrial dysfunction in our APP cell 
model, especially the decrease in complex IV activity, is already observed at picomolar 
concentrations and higher amounts of synthetic Aß are needed to achieve a comparable 
mitochondrial impairment highlights also the potential role of other APP fragments, e.g. the 
carboxy-terminal APP fragments (CTFs), which may accelerate the Aß-induced 
mitochondrial failure (Jin et al., 2002; Chang and Su, 2005). This is of special interest, since 
both, Aß and CTFs, can accumulate intraneuronally. The neuronal loss and synaptic 
transmission deficit in AD may therefore depend on intraneuronal accumulation of Aß and 
CTFs (Jin et al., 2002; Chang and Su, 2005). Similarly, we showed that energy production 
was impaired in the APP cells, which is corroborated with other findings (Hauptmann et al., 
2008; Keil et al., 2004). 
 
One can speculate that in humans increased accumulation and associated 
mitochondrial toxicity can be underlying factors in the pathogenesis of AD. Initially, the 
damaging effects of low physiological concentrations of Aß may be partly compensated by an 
adaptive response, e.g. increased complex III activity. However, when age-related secondary 
stress occurs, pronounced mitochondrial impairment might lead to the induction of cell death 
processes, while in familial AD, high Aß load might be directly responsible for mitochondrial 
and cellular dysfunction. In summary, we show novel and distinct actions of Aß on 
mitochondria that may contribute to the pathogenic outcome. 
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MATERIAL AND METHODS 
 
Cell culture. Stably expressing cell lines were obtained by transfecting the human 
neuroblastoma SH-SY5Y with cDNAs (pCEP4 vector) containing either vector alone (control 
cells) or the entire coding region of human APP (APP695) (Scheuermann et al. 2001). Stably 
transfected cell clones were selected with hygromycin (Scheuermann et al. 2001). Cells were 
grown at 37oC in DMEM medium supplemented with 10% calf serum, 2mM L-glutamine, 
and 0.3µg/ml hygromycin. 
 
Detection of Aß levels. For the detection of secreted Aß1-40, we used a specific sandwich 
enzyme-linked immunosorbent assay employing monoclonal antibodies (Keil et al. 2004). 
The ELISA was performed in accordance to the Abeta-ELISA Kit by Biosource. The assay 
principle is that of a standard sandwich ELISA, which utilizes a monoclonal mouse anti-
human Abeta1-16 capture antibody, a cleavage-site-specific rabbit anti-human Abeta1-40 C-
terminal detection antibody and anti-rabbit IgG peroxidase-conjugated secondary antibody.  
 
Western blot. Equal amounts (10-20 µg) of protein were loaded on a 4-20% acryamide gel 
(Invitrogen, Germany) to perform SDS-PAGE at 200 V for 50mn. The probes were 
transferred to a PVDF membrane (Amersham Biosciences, Germany). Equal protein loading 
was confirmed by Ponceau Red staining (Sigma, Germany). Membranes were saturated with 
5% nonfat dry milk for one hour, washed three times with TBST and incubated with the 
primary antibody (monoclonal anti-APP/Aß W02, Stratech, UK, or anti-actin, Santa Cruz, 
Germany), overnight at 4°C. After washing with TBST, PVDF membranes were treated with 
anti-IgG, horseradish-coupled secondary antibody (Calbiochem, Germany), for one hour at 
room temperature. The bands were specifically detected by enhanced chemiluminescence 
reaction (ECL, Amersham, Germany). 
 
Immunohistochemical staining. Cells were plated at a density of 4x105 cells on collagen 
treated coverslips. After two days growing, coverslips were fixed in PBS with 4% PFA at 37° 
for 30mn, then permeabilized with 0.1% Triton for 15mn and blocked with PBS 10% goat 
serum for 1h at 37°C. The coverslips were incubated for 1h at 37°C with the primary antibody 
(monoclonal mouse anti-APP MAB348, Chemicon International, Switzerland, which 
recognizes amino acids 66-81 of the N-terminal of APP). After washing with PBS, they were 
incubated for 30mn at 37°C with the secondary antibody anti-mouse IgG biotinylated (Sigma, 
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Switzerland). Then, they were incubated with Vectastain ABC reagent (Vector Laboratories 
Inc., Burlingame) containing avidin and horseradish peroxidase reagents for 
immunoperoxidase staining. Finally, slides were incubated with AEC substrate solution 
(Sigma, Switzerland) containing 3-amino-9-ethyl carbazole for localizing peroxidase in the 
cells by producing a red reaction product. Staining was assessed using a Zeiss Axiolab 
microscope. Black-and-white photographs were taken. 
 
Phase contrast microscopy and morphological anlysis. For the morphological analysis, 
cells were seeded at a density of 4x104 cells/ml on coverslips previously coated with 0.05 
mg/mL collagen. Phase contrast pictures were taken from living neuroblastoma cells using a 
Zeiss Axiolab microscope equipped with a digital camera Zeiss AxioCam MRc. 
 
Preparation of isolated mitochondria. Cells were incubated for 15mn in an ice-cold lysis 
buffer (75mM NaCl, 1mM NaH2PO4, 8mM Na2HPO4, 250mM sucrose, 1mM Pefabloc, 
0.05% digitonine, complete protease inhibitor mixture tablets® (Roche Diagnostics). Then, the 
cells were homogenized with a glass homogenizer (10 strokes at 400rpm and 5 strokes at 
700rpm), and the resulting homogenate was centrifuged at 800 x g for 10mn at 4°C to remove 
nuclei and tissue particles. The supernatant 1 (S1) was saved and the pellet resuspended in the 
lysis buffer. The homogenization step as well as the low-speed centrifugation step was 
repeated. The supernatant 2 (S2) was saved and added to the supernatant 1. The combined 
mitochondria-enriched supernatants (S1+S2) were centrifuged at 20,000 x g for 15mn at 4°C 
to obtain the mitochondrial fraction. The pellet was resuspended in PBS and stored at 4°C 
until use, followed by determination of protein content (Lowry et al. 1951). 
  
Complex I activity. A total of 300µg of isolated mitochondria was solubilized in n-dodecyl 
β-D-maltoside (20%). NADH:hexaammineruthenium(III)-chloride (HAR) activity was 
measured at 30 °C in a buffer containing 2mM Na+/MOPS, 50mM NaCl, and 2mM KCN, pH 
7.2, using 2mM HAR and 200µM NADH, as substrates to estimate the complex I content. To 
determine NADH-ubiquinone oxidoreductase activity, 100µM n-decylubiquinone (DBQ) and 
100µM NADH were used as substrates and 5µM rotenone as inhibitor, as described 
previously (David et al. 2005; Djafarzadeh et al. 2000; Hauptmann et al. 2008). Oxidation 
rates of NADH were recorded with a Shimadzu Multi Spec-1501 diode array 
spectrophotometer (ε340-400nm = 6.1 mM-1.cm-1). Complex I activity was normalized to the 
complex I content of the mitochondrial preparation and is given as DBQ/HAR ratio.  
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Complex II activity. The assay was performed by following the decrease in absorbance at 
600 nm, which results in the reduction of 2,6-dichlorophenolindo-phenol (DCIP) in 1ml of 
medium containing 60mM KH2PO4 (pH 7.4), 3mM KCN, 20µg/mL rotenone, 20mM 
succinate, and 20µg mitochondrial protein. The reaction was initiated by the addition of 
1.3mM phenazine methasulfate (PMS) and 0.18mM DCIP as described previously (Aleardi et 
al. 2005).The extinction coefficient used for DCIP was 21mM−1 .cm−1. 
 
Complex III activity. The oxidation of 50µM decylubiquinol obtained by complex III was 
determined using cytochrome c as an electron acceptor as described previously (Krahenbuhl 
et al. 1991). Briefly, decylubiquinol is prepared by dissolving decylubiquinone (10mM) in 
ethanol acidified to pH 2. The quinone is reduced with excess solid sodium borohydride. 
Decylubiquinol is extracted into diethylether:cyclohexane (2:1, v/v) and evaporated to 
dryness under nitrogen gas, dissolved in ethanol acidified to pH 2. The assay was carried out 
in a medium containing 35mM KH2PO4, 5mM MgCl2, 2mM KCN (pH 7.2), supplemented 
with 2.5mg/mL BSA, 15µM cytochrome c, 0,6mM n-dodecyl β-D-maltoside and 5µg/mL 
rotenone. The reaction was started with 10µg of mitochondrial protein and the enzyme 
activity was measured at 550 nm. The extinction coefficient used for cytochrome c was 
18.5mM−1.cm−1. 
 
Complex IV activity. Cytochrome c oxidase activity was determined in intact isolated 
mitochondria (100µg) using Cytochrome c Oxidase Assay Kit. The colorimetric assay is 
based on the observation that a decrease in absorbance at 550 nm of ferrocytochrome c is 
caused by its oxidation to ferricytochrome c by cytochrome c oxidase. The Cytochrome c 
Oxidase Assay was performed as described previously (Rasmussen and Rasmussen 2000). 
 
Mitochondrial respiration in vital cells. Mitochondrial oxygen consumption was measured 
at 37°C using an Oroboros Oxygraph-2k system. Five millions of cells were added to 2ml of a 
mitochondrial respiration medium containing 0.5mM EGTA, 3mM MgCl2, 60mM K-
lactobionate, 20mM Taurine, 10mM KH2P04, 20mM HEPES, 110mM Sucrose, 1g/l BSA (pH 
7.1). To measure the state 4 (= state 2) of the complex I, 5mM pyruvate and 2mM malate 
were added and cells were permeabilised with 15µg/ml digitonin. Afterwards, 2mM ADP is 
added to measure state 3 respiration, and, in order to increase the respiratory capacity, 10mM 
glutamate was added. To study the effect of the convergent complex I+II electron input on the 
respiration, 10mM of succinate was added. The integrity of the mitochondrial membrane was 
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checked through the addition of 10uM cytochrome c. After determining coupled respiration, 
0.4µM FCCP (Carbonyl cyanide p-(trifluoro-methoxy) phenyl-hydrazone) was added and 
respiration was measured in the absence of a proton gradient. In order to inhibit complex I 
and III activities 0.5uM rotenone and 2.5uM antimycine A, respectively were added. Mock 
and APP cells were measured in parallel pairs using the same conditions (crossover design). 
 
Citrate synthase activity. The reduction of 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) by 
citrate synthase at 412 nm (extinction coefficient of 13.6mM-1.cm-1) was followed in a 
coupled reaction with coenzyme A and oxaloacetate (Aleardi et al. 2005). Briefly, a reaction 
mixture of 0.2M Tris-HCl, pH 8.0, 0.1mM acetyl-coenzymeA, 0.1mM DTNB, n-dodecyl-β-
D-maltoside (20%) and 10g of mitochondrial protein was incubated at 30°C for 5 min. The 
reaction was initiated by adding 0.5mM oxaloacetate, and the absorbance change was 
monitored for 5min with a Shimadzu Multi-Spec-1501 diode array spectrophotometer. 
 
Determination of ATP levels. Cells were plated one day before at a density of 2.5 x 104 
cells/ well in a white 96 well plate. The kit is based on the bioluminescent measurement of 
ATP. The bioluminescent method utilizes the enzyme luciferase, which catalyses the 
formation of light from ATP and luciferin. The emitted light was linearly related to the ATP 
concentration and was measured using a luminometer (David et al. 2005; Keil et al. 2004).  
 
Statistical Analysis. Data are presented as mean ± S.E.M. For all statistical comparison, 
Student’s t-test or Two-way ANOVA was used. P values less than 0.05 were considered 
statistically significant. 
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ABSTRACT 
 
Background: Energy deficiency and mitochondrial failure have been recognized as a 
prominent, early event in Alzheimer’s disease (AD). Recently, we demonstrated that chronic 
exposure to amyloid-beta (Aβ) in human neuroblastoma cells over-expressing human wild-
type amyloid precursor protein (APP) resulted in (i) activity changes of complexes III and IV 
of the oxidative phosphorylation system (OXPHOS) and in (ii) a drop of ATP levels which 
may finally instigate loss of synapses and neuronal cell death in AD. Therefore, the aim of the 
present study was to investigate whether standardized Ginkgo biloba extract LI 1370 (GBE) is 
able to rescue Aβ-induced defects in energy metabolism.  
Methodology: We used a high-resolution respiratory protocol to investigate OXPHOS 
respiratory capacity and metabolic states under physiological condition in vital control and 
APP cells after treatment with GBE. In addition, oxygen consumption of isolated 
mitochondria, activities of mitochondrial enzymes (complexes I-IV and citrate synthase), 
ATP levels, mitochondria amount, and mitochondrial DNA content were determined.  
Principal Findings: We observed a GBE-induced increase of the coupling state of 
mitochondria resulting in an improvement of the OXPHOS efficiency in both cell lines, with 
the strongest enhancing effect in APP cells. GBE effect on OXPHOS was even preserved in 
mitochondria after isolation from treated cells. The GBE-induced amelioration of oxygen 
consumption most likely arose from the modulation and respective normalization of the 
activity of mitochondrial complexes I, III and IV that are markedly disturbed in APP cells 
finally yielding a rise in ATP levels. Of note, these functional data were paralleled by an up-
regulation of mitochondrial DNA in GBE-treated cells.  
Conclusions/Significance: Although the underlying molecular mechanisms of the mode of 
action of GBE remain to be determined, our study clearly highlights the beneficial effect of 
GBE on the cellular OXPHOS performance leading to retrieval of Aβ-induced mitochondrial 
dysfunction.  
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INTRODUCTION 
 
Standardized Ginkgo biloba extract (GBE) derived from dried leaves of Ginkgo tree is 
a valuable therapeutic drug for the treatment of memory impairment and dementia including 
Alzheimer’s disease (AD). Double-blind, placebo-controlled studies showed the improvement 
of cognitive symptoms in the elderly and in AD patients [1-5]. GBE exhibits a complex mode 
of action. Notably, multiple effects on mitochondrial function and on the apoptotic pathway 
that seems to be crucial for its beneficial effects in AD were reported: stabilization of 
mitochondrial membrane potential, improvement of energy metabolism, up-regulation of anti-
apoptotic Bcl-2 protein and down-regulation of pro-apoptotic Bax protein, inhibition of 
cytochrome c release, reduction of caspase 9 and caspase 3 activity after oxidative stress and 
reduction of apoptotic cell death [6-12]. However, evidence how GBE influences the 
mitochondrial oxidative phosphorylation system (OXPHOS) in neuronal cells is lacking. 
AD is characterized by amyloid-beta (Aβ)-containing plaques, neurofibrillary tangles, 
as well as synapse and neuron loss. Aβ which represents with tau the main neuropathological 
hallmarks of AD is supposed to play a pivotal role in the pathogenesis of the disease. Within 
the Aβ toxicity cascade, mitochondrial dysfunction and energy metabolism deficiencies have 
been recognized as earliest events [8, 13] and have been correlated with impairments of 
cognitive abilities in AD clinical scenario [14]. The most consistent defect in mitochondrial 
electron transport chain enzymes in AD is the deficiency in cytochrome c oxidase (complex 
IV) activity in post-mortem brain tissues of AD patients [15-17] and APP transgenic mice 
[18], as well as in other tissues, such as platelets from AD patients and AD cybrid cells [19, 
20]. Interestingly, few years ago, the target of interest of Aβ toxic species switched from its 
extracellular, fibrillar form to its soluble, oligomeric form [21, 22] emphasising the important 
early role of mitochondria in AD pathogenic pathways [8, 23-25].  
 
In line with these findings, we recently reported that chronic exposure to Aβ in human 
neuroblastoma cells (SH-SY5Y) over-expressing human wild-type APP (APP cells) resulted 
in an impairment of the respiratory capacity of OXPHOS and a drop in ATP generation by 
complex V which in turn may initiate cell death pathway [26]. 
 
Therefore, the aim of the present study was to investigate the potential effect of 
standardized GBE LI 1370 on Aβ-induced mitochondrial dysfunction in APP cells. In 
addition to the measurement of oxygen consumption in whole cells as well as of isolated 
 95 
mitochondria, we examined activities of mitochondrial enzymes assembling the electron 
transport system (ETS) that are the complexes I to IV, the activity of citrate synthase, an 
enzyme located in the mitochondrial matrix those activity is reported to be very proportional 
to the content of ETS enzymes within mitochondria [27], ATP levels and mitochondria mass. 
Finally, we studied the mitochondrial DNA / nuclear DNA ratio using real-time PCR to 
determine changes at the genetic level. 
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RESULTS 
 
GBE did not modify cells morphology but decreased amount of mitochondria. As 
described in our previous study [26], transfection of SH-SY5Y cells with cDNAs (pCEP4 
vector) containing the vector alone or the entire coding region of human APP (APP695) did 
not significantly change the general morphological aspect of cells (Fig 1A). Similarly, vector 
control as well as APP cells conserved their neuroblast-like morphology with differentiated 
perikaria and short neurites after treatment with GBE (Fig 1B). However, using a 
MitoTracker GreenTM, we observed a decrease of mitochondria amount in GBE-treated 
control and APP cells, with the strongest effect in APP cells (Fig. 1C). In accordance with this 
result, citrate synthase (CS) activity, which is commonly used as a quantitative measure of the 
content of mitochondria and ETS enzymes [27], was also reduced in GBE-treated control and 
APP cells (Fig. 1D).  
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Fig.1 GBE did not modify cell morphology but mitochondrial amount. Morphological analysis of vector 
control and APP cells showed neuroblast-like morphology with differentiated perikaria (arrows) and occasional 
short neurites (arrowheads). A) Transfection of SH-SY5Y cells with cDNAs (pCEP4 vector) containing the vector 
alone or the entire coding region of wild-type human APP (APP cells) and B) GBE treatment (0.1mg/ml; 24h) did 
not significantly change general cell morphology. Scale bars: 50µm. C) A decrease of mitochondria amount was 
measured in GBE-treated cells using MitoTracker GreenTM. D) A decrease of citrate synthase activity (CS) was 
observed in GBE-treated cells. Values represent the means ± S.E. from n= 5 assays, student’s t-test: #, p<0.05; ###, 
p<0.001 versus corresponding untreated cells. 
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GBE ameliorated OXPHOS capacity and restored Aβ-induced deficits in vital cells. To 
investigate the protective effect of GBE against Aβ toxicity at the mitochondrial level, we 
used a high-resolution respiratory protocol established lately by our group [26]. Thus, 
physiological substrate combinations (pyruvate, glutamate and malate as substrates for 
complex I and succinate for complex II) were used to obtain mitochondrial bioenergetics 
approaching the most of physiological states (Fig. 2A). We compared OXPHOS that is the 
whole ETS composed of the four mitochondrial enzymes (complex I to complex IV) and the 
F1F0ATP synthase of vital control and APP cells after pre-treatment with GBE for 24h. As 
previously observed [26], APP cells exhibited an impairment of OXPHOS capacity (Fig, 2B). 
Of note, GBE was able to significantly ameliorate the global failure of mitochondrial 
respiration in APP cells and increased oxygen consumption in control cells as well (Fig. 2B). 
Importantly, GBE-treated control and APP cells presented comparable mitochondrial 
respiratory rate validating the protective role of GBE on stabilization and normalization of 
mitochondrial capacity, respectively (Fig. 2B).  
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Fig.2 High-resolution respirometry 
revealed an improvement of 
mitochondrial capacity of vital cells 
after GBE treatment. A) 
Representative diagram of 
measurement of oxygen (O2) 
consumption in GBE-treated APP 
cells. O2 flux and O2 consumption by 
vital cells were measured after 
addition of different agents: 
pyruvate/glutamate (pyr/glu), 
digitonin (dig), ADP, glutamate (glu), 
succinate (suc), cytochrome c (cyt c), 
FCCP, rotenone (rot), antimycine A 
(AA). B) Two-way ANOVA revealed 
a significant Aβ-induced decrease of 
the cellular respiration in APP cells 
compared to that of control cells 
(p<0.001). Two-way ANOVA 
revealed also a significant effect of 
GBE on O2 consumption. Indeed, 
respiratory rates of mitochondria were 
increase in GBE-treated control and 
APP cells corresponding to that of 
their respective cell type (p<0.001). 
Values represent the means ± S.E. 
from n= 5 assays (measurements of 
control and APP cells were performed 
in parallel). 
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To analyse the impact of GBE on metabolic states of mitochondrial respiration, two 
flux control ratios have been evaluated. First, the respiratory control ratio (RCR3/4) which is 
an indicator of the coupling state of mitochondria was determined. State 3 is the rate of 
phosphorylating respiration in the presence of exogeneous ADP, when mitochondria are 
actively making ATP, whereas state 4 is the rate of resting respiration, when all ADP has been 
consumed. State 4 is associated with proton leakage across the inner mitochondrial 
membrane, when mitochondria exhibit basal activity, i.e. they are respiring but not making 
ATP. Therefore, RCR3/4 represents the ADP-activated flux to measure coupled OXPHOS 
capacity (state3) divided by leak flux (state4). Whereas increased Aβ levels led to a decrease 
of RCR3/4 in APP cells, treatment with GBE significantly increased the ratio in both cell 
types (Fig. 3A). Secondly, ROX/ETS yields an index of the magnitude of residual oxygen 
consumption relative to maximum oxygen
 
consumption capacity. This ratio was decreased in 
both cell types after treatment with GBE with the strongest effect in APP cells (Fig. 3B). Both 
flux control ratio changes indicate an increase of the coupling state of mitochondria leading to 
a better efficiency of OXPHOS. Consistent with this result, we observed a rise of ATP levels 
produced by complex V, the final OXPHOS enzyme, in GBE-treated control and APP cells 
(Fig. 3C).  
 
 
 
 
 
 
 
 
 
 
 
 
Taken together, respiratory analyses showed that GBE enhanced metabolic pathways 
by increasing the coupling state of OXPHOS promoting finally a rise of ATP synthesis in 
both cell types but with the strongest effects on APP cells. As a consequence, GBE-treated 
control and APP cells presented comparable mitochondrial respiratory system capacity 
suggesting a complete restoration of Aβ-induced deficits in energy metabolism. 
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Fig.3 GBE modulated mitochondrial flux control ratios and rose ATP synthesis. A) Respiratory control 
ratio (RCR3/4) represents the mitochondrial coupling state. RCR3/4 was decreased in APP cells and increased in 
GBE-treated control and APP cells. B) ROX/ETS yields an index of the magnitude of residual oxygen 
consumption relative to the maximum oxygen
 
consumption capacity. This ratio was decreased in GBE-treated 
control and APP cells. C) ATP levels were decreased in APP cells and increased in GBE-treated control and 
APP cells. Values represent the means ± S.E. from n= 5 assays, student’s t-test: *, p<0.05; ***, p<0.001 versus 
control cells; #, p<0.05; ##, p<0.01 versus corresponding untreated cells. 
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GBE improved oxygen consumption in isolated mitochondria from APP cells and led to 
an up-regulation of mitochondrial DNA. To confirm the improvement of mitochondrial 
performance observed in whole cells, we investigated oxygen consumption of mitochondria 
that were isolated form APP cells after 24h treatment with GBE. In isolated mitochondria, the 
GBE-induced enhancement of oxygen consumption was still significantly present (Fig. 4A) 
suggesting a regulatory effect of GBE at the mitochondrial level even after its removal. Of 
note, this functional enhancement can be associated with an increase of the mitochondrial 
DNA / nuclear DNA ratio after treatment with GBE (Fig. 4B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GBE modulated the activity of respiratory complexes. To improve the mitochondrial 
respiratory capacity, GBE may act on one or several mitochondrial enzyme. To study this 
hypothesis, the activities of individual respiratory complexes have been investigated. 
Complex I activity was significantly increased in GBE-treated APP cells (Fig 5A). Complex 
III activity which is markedly increased in APP cells was normalized to the level of control 
cells after treatment with GBE (Fig. 5B). Complex IV activity which is decreased in APP 
cells, significantly increased in control and APP cells after treatment with GBE (Fig. 5C). 
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Fig.4 GBE enhanced oxygen consumption of isolated mitochondria from APP cells and led to an up-
regulation of mitochondrial DNA. A) Two-way ANOVA revealed a significant effect of GBE on respiratory 
rates of isolated mitochondria from APP cells. The oxygen consumption was increased in mitochondria isolated 
from GBE-treated APP cells when compared to that of untreated APP cells (p<0.001). B) RT-PCR analyses 
revealed an increase of the mitochondrial DNA / nuclear DNA ratio from GBE-treated control and APP cells 
compared to their corresponding untreated cells (#, p<0.05). Values represent means ± S.E. from n=5 assays. 
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Fig.5 GBE modulated activities of mitochondrial ETS enzymes. A) Complex I activity (CI/CS ratio) was 
increased in GBE-treated APP. B) Complex III activity (CIII/CS ratio) was increased in APP cells and decreased 
in GBE-treated APP cells. C) Complex IV activity (CIV/CS ratio) was decreased in APP cells and increased in 
GBE-treated control and APP cells. All values represent the means ± S.E. from n= 4-6 assays, student’s t-test: 
**, p<0.01, ***, p<0.001 versus control cells; #, p<0.05, ##, p<0.01 versus corresponding untreated cells. 
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DISCUSSION  
 
 To pinpoint the mode of action of GBE on mitochondrial function as well as on Aβ-
induced OXPHOS failure, we first measured oxygen consumption in vital cells. This 
approach facilitates the determination of the capacity of the whole OXPHOS as well as flux 
control ratios (RCR3/4 and ETS/ROX) widely recognized as indicators of metabolic states of 
mitochondrial respiration [28]. In the present study, we present for the first time clear 
evidence that under physiological conditions mimicked in our respiratory whole cell protocol, 
GBE improved metabolic energy pathways by increasing the coupling state of mitochondria. 
Importantly, the comparability of the mitochondrial energetic capacity in both cell types after 
treatment with GEB indicates a recovery of the disturbed bioenergetics homeostasis found in 
APP cells. Notably, GBE-enhancing effect on OXPHOS was still present in mitochondria 
after removal of mitochondria from the cells suggesting possible continuing, regulatory 
actions of GEB at the mitochondrial level. These results corroborate findings showing an 
increase of the coupling state of isolated mitochondria by GBE in ischemia models [29] and 
findings demonstrating that GBE ameliorated oxygen consumption of mitochondria from rat 
heart mainly driven by effects of GBE on complex I and III [30]. The capacity of 
mitochondria to re-phosphorylate ADP in state 3 is positively dependent on the degree of 
coupling. In accordance with this assumption, we also observed an enhancement of ATP 
levels in both cell types after treatment with GBE. Moreover, the respiration rate in state 3 is 
determined by the activity of mitochondrial enzymes of the whole ETS and ATP-synthase 
[30, 31]. Thus, the global improvement of mitochondria functionality may be explained by the 
action of GBE on one or several mitochondrial enzymes. To test this hypothesis, we measured 
individual activities of mitochondrial enzymes belonging to the ETS. The increased activity 
of complex III in APP cells that can be interpreted as a compensatory mechanism to rescue 
Aβ-induced mitochondrial defects [26] normalized after treatment with GBE. This effect can 
be taken as a back to a physiological functionality, i.e. the over-activity of complex III in 
untreated APP cells was down-regulated in the presence of GBE which in turn up-regulated 
complex IV activity and ATP synthesis, both markedly reduced in our AD cell model. 
Interestingly, complex I activity was increased in APP cells after treatment with GBE while it 
was unchanged in APP cells per se. GBE by increasing the coupling mitochondrial state may 
improve complex I activity. Moreover, complex I due to its first position in ETS plays a 
crucial role in energy metabolism and oxidative phosphorylation. Indeed, a partial decrease of 
its activity (about 25%) is sufficient to alter severely the mitochondrial respiration [32]. 
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Complex I as a main ROS producer may also be a key element in GBE efficacy. In an 
ischemic model, the increase of coupling state of mitochondria was also associated with a 
protection of the activities of complexes I and III by GBE [33]. Our study is further in line 
with recent findings studying the effect of GBE after in vivo treatment on mitochondrial 
membrane potential in dissociated brain cells from aged mice after inhibiting OXPHOS using 
specific inhibitors of complexes [9]. Here, GEB showed protective effects on mitochondrial 
membrane potential at the complexes I, IV and V [9]. Even if the exact molecular 
mechanisms by which GBE stabilizes mitochondrial enzymes is not yet clear, it can be 
speculated that besides other regulatory effects on mitochondria components: (i) GBE may act 
as an antioxidant scavenging superoxide anion generated by electron leakage which occurs 
mainly at complexes I and III. (ii) GBE may also scavenge nitric oxide leading to an increase 
of complex IV activity which is the main target of NO [34]. Consequently, the protection of 
mitochondrial complexes by GBE may not only lead to an increase of mitochondrial 
performance (coupling state) but also to a decrease of ROS production. In accordance with 
this idea, some authors proposed that GBE provides anti-apoptotic effects [6, 7, 35]. Thus, 
GBE significantly attenuated mitochondria-initiated apoptosis and decreased the activity of 
caspase 3, a key enzyme in the apoptosis cell signalling cascade, in neuroblastoma cells stably 
expressing an AD-associated double mutation in APP [10]. In addition, GBE inhibited 
formation of Aβ-fibrils [10] either by a direct interaction with Aβ [36, 37] or by activating α-
secretase pathway [38].  
 
 Of note, we observed an up-regulation of mitochondrial DNA in cells treated with GBE, 
but at the same time, a decrease of mitochondria mass in GBE-treated cells suggesting that 
GBE may act not only at a functional level but also at a genetic one. The number of 
mitochondrial DNA copies per mitochondrion as well as mitochondria per cell is exquisitely 
calibrated on cellular energy demand. The fact that an increased content of mitochondrial 
DNA encoding for important core subunits of the OXPHOS is associated with an increased 
OXPHOS performance suggest that possibly the assembly of mitochondrial super complexes 
is facilitated coupled to an increased activity. Accordingly, Tendi and colleagues [35] showed 
that GBE up-regulated mitochondrial gene expression of a mtDNA encoded subunit of 
complex I (ND1) in PC12 cells which may perfectly correspond to the increase of complex I 
activity detected in GBE-treated APP cells. Moreover, the transcript level of the anti-
apoptotic Bcl-2-like protein was found to be elevated, whereas the transcript level of the pro-
apoptotic caspase 12 was decreased in PC12 cells after treatment with GBE [7, 10]. Although 
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further studies are necessary, we can speculate that a GBE treatment may not only enhance 
mtDNA but may modulate mitochondria biogenesis after chronic exposure. In line with this 
idea, a recent study showed that GBE induced hippocampal neurogenesis, a very energy 
demanding process, in young and old transgenic AD mouse model (TgAPP/PS1) after 
receiving a diet supplemented with GBE for 1 month [39].  
 
In total, our findings and the findings of others indicate substantial mitochondria 
modulating properties of GBE. We could clearly show that GBE improved OXPHOS 
performance and was able to restore Aβ-induced mitochondria failure. Hereby, the increase in 
mitochondrial content might represent an important early event. Taking into account the 
increasing interest in mitochondrial stabilization as intervention strategy in AD, the regulating 
mechanisms of GBE on mitochondria function suggested by this study qualifies this drug as 
therapeutic candidate. 
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MATERIAL AND METHODS  
 
Cell culture. Stably expressing cell lines were obtained by transfecting human neuroblastoma 
SH-SY5Y with cDNAs (pCEP4 vector) containing either the vector alone (control cells) or 
the entire coding region of human wild-type APP (APP695) [40]. APP cells secreted Aβ 
levels within pg/mL range (around 150 pg/mL Aβ1-40 compared to approximately 50 pg/mL 
Aβ1-40 secreted by vector control cells) [26]. Stably transfected cell clones were selected 
with hygromycin [40]. Cells were grown at 37oC in DMEM medium supplemented with 10% 
calf serum, 2mM L-glutamine, and 0.3µg/ml hygromycin. Cells were pre-treated with 
0.1mg/ml of standardized Ginkgo biloba extract LI 1370 (Vifor SA, Switzerland), for 24h 
before analyzing the cells. In pre-experiments, we excluded effects of the vehicle. 
 
Phase contrast microscopy and morphological anlysis. For the morphological analysis, 
cells were seeded at a density of 4x104 cells/ml on coverslips previously coated with 0.05 
mg/mL collagen. Phase contrast pictures were taken from living neuroblastoma cells using a 
Zeiss Axiolab microscope equipped with a digital camera Zeiss AxioCam MRc. 
 
Preparation of isolated mitochondria. Cells were incubated for 15min in an ice-cold lysis 
buffer (75mM NaCl, 1mM NaH2PO4, 8mM Na2HPO4, 250mM sucrose, 1mM Pefabloc, 
0.05% digitonine, complete protease inhibitor mixture tablets® (Roche Diagnostics). Then, 
cells were homogenized with a glass homogenizer (10 strokes at 400rpm and 5 strokes at 
700rpm), and the resulting homogenate was centrifuged at 800g for 10min at 4°C to remove 
nuclei and tissue particles. The supernatant 1 (S1) was saved and the pellet resuspended in the 
lysis buffer. The homogenization step as well as the low-speed centrifugation step was 
repeated. The supernatant 2 (S2) was saved and added to the supernatant 1. Combined 
mitochondria-enriched supernatants (S1+S2) were centrifuged at 20,000g for 15min at 4°C to 
obtain the mitochondrial fraction. The mitochondrial pellet was resuspended in PBS and 
stored at 4°C until use, followed by determination of protein content [41]. 
 
Citrate synthase activity. The reduction of 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) by 
citrate synthase at 412 nm (extinction coefficient of 13.6mM-1.cm-1) was followed in a 
coupled reaction with coenzyme A and oxaloacetate [26, 27]. Briefly, a reaction mixture of 
0.2M Tris-HCl, pH 8.0, 0.1mM acetyl-coenzymeA, 0.1mM DTNB, n-dodecyl-β-D-maltoside 
(20%) and 10µg of mitochondrial protein was incubated at 30°C for 5 min. The reaction was 
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initiated by adding 0.5mM oxaloacetate, and the absorbance change was monitored for 5min 
with a Shimadzu Multi-Spec-1501 diode array spectrophotometer. CS activity is given as 
units per mg mitochondrial protein [U/mg]. CS is commonly used as a quantitative marker 
enzyme for the content of mitochondria and ETS, respectively. In the following experiments, 
mitochondrial respiration and complex raw activities, therefore, are expressed per CS activity 
to take into account variations in the amount of mitochondrial and non-mitochondrial protein 
contamination between the samples [26, 27]. 
 
Complex I activity. A total of 240µg of isolated mitochondria was solubilized in n-dodecyl 
β-D-maltoside (20%). NADH-ubiquinone oxidoreductase activity was measured at 30 °C in a 
buffer containing 2mM Na+/MOPS, 50mM NaCl, and 2mM KCN, pH 7.2, using 100µM n-
decylubiquinone (DBQ) and 100µM NADH as substrates and 5µM rotenone as inhibitor [18, 
26, 42, 43]. Oxidation rate of NADH were recorded with a Shimadzu Multi-Spec-1501 diode 
array spectrophotometer (ε340-400nm = 6.1mM-1.cm-1). Complex I activity was normalized to 
citrate synthase activity and is given as CI/CS ratio.  
 
Complex III activity. The oxidation of 50µM decylubiquinol obtained by complex III was 
determined using cytochrome c as an electron acceptor as described previously [26, 44]. 
Briefly, decylubiquinol was prepared by dissolving decylubiquinone (10mM) in ethanol 
acidified to pH 2. The quinone was reduced with excess solid sodium borohydride. 
Decylubiquinol was extracted into diethylether:cyclohexane (2:1, v/v) and evaporated to 
dryness under nitrogen gas, dissolved in ethanol acidified to pH 2. The assay was carried out 
in a medium containing 35mM KH2PO4, 5mM MgCl2, 2mM KCN (pH 7.2), supplemented 
with 2.5mg/mL BSA, 15µM cytochrome c, 0,6mM n-dodecyl β-D-maltoside and 5µg/mL 
rotenone. The reaction was started with 10µg of mitochondrial protein and the enzyme 
activity was measured at 550nm. The extinction coefficient used for cytochrome c was 
18.5mM−1.cm−1. Complex III activity was normalized to citrate synthase activity and is given 
as CIII/CS ratio.  
 
Complex IV activity. Cytochrome c oxidase activity was determined in intact isolated 
mitochondria (100µg) using the Cytochrome c Oxidase Assay Kit. The colorimetric assay was 
based on the observation that a decrease in absorbance at 550nm of ferrocytochrome c was 
caused by its oxidation to ferricytochrome c by cytochrome c oxidase. The Cytochrome c 
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Oxidase Assay was performed as described previously [26, 43, 45]. Complex IV activity was 
normalized to citrate synthase activity and is given as CIV/CS ratio.  
 
Mitochondrial respiration in vital cells. Mitochondrial oxygen consumption was measured 
at 37°C using an Oroboros Oxygraph-2k system. Five millions of cells were added to 2ml of a 
mitochondrial respiration medium containing 0.5mM EGTA, 3mM MgCl2, 60mM K-
lactobionate, 20mM Taurine, 10mM KH2P04, 20mM HEPES, 110mM Sucrose, 1g/l BSA (pH 
7.1). To measure state 4 (= state 2) of complex I, 5mM pyruvate and 2mM malate were added 
and cells were permeabilised with 15µg/ml digitonin. Afterwards, 2mM ADP was added to 
measure state 3, and in order to increase the respiratory capacity, 10mM glutamate was added. 
To study the effect of convergent complex I+II electron input on respiration, 10mM of 
succinate was added [28]. The integrity of mitochondrial membrane was checked through the 
addition of 10uM cytochrome c. After determining coupled respiration, 0.4µM FCCP 
(Carbonyl cyanide p-(trifluoro-methoxy) phenyl-hydrazone) was added and respiration was 
measured in the absence of a proton gradient. In order to inhibit complex I and III activities 
0.5uM rotenone and 2.5uM antimycine A, respectively were added. Then, 2mM ascorbate and 
0.5mM TMPD were added to have access to complex IV activity. Finally, 100mM sodium 
azide was added to inhibit the mitochondrial respiration. Mock and APP cells untreated or 
treated with GBE were measured in parallel pairs using same conditions (crossover design). 
 
Oxygen consumption of isolated mitochondria. The respiratory protocol used for 
mitochondria was the same than this for whole cells except for the following points: (i) 
isolated mitochondria (0.5mg) were added to 2ml of a mitochondrial respiration medium 
containing 65mM sucrose, 10mM potassium phosphate, 10mM Tris-HCl, 10mM MgSO4, and 
2mM EDTA (pH 7.0), (ii) digitonin was not added and (iii) 0.05µM of FCCP was sufficient to 
obtain the maximal mitochondrial respiration [43]. 
 
Determination of ATP levels. Cells were plated one day before at a density of 2.5 x 104 
cells/well in a white 96 well plate. The assay kit is based on the bioluminescent measurement 
of ATP. The bioluminescent method utilizes the enzyme luciferase, which catalyses the 
formation of light from ATP and luciferin. The emitted light was linearly related to ATP 
concentration and was measured using a luminometer [43, 46].  
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Amount of mitochondria. Cells were plated at a density of 100 000 cells/well in a 48 well 
plate. The total amount of mitochondria was measured using the cell-permeable 
mitochondria-selective dye MitoTracker GreenTM (400nM, 15min). This probe can 
accumulate in active mitochondria independently of mitochondrial membrane potential and 
then react with accessible thiol groups of proteins and peptides [47]. Fluorescence was 
determined using a Fluoroskan Ascent FL multiplate reader (Labsystems) at 490nm 
(excitation) / 516nm (emission). 
 
Quantitative real-time PCR for determination of mitochondrial DNA / nuclear DNA 
ratio. Total DNA was extracted with the Qiagen FlexiGen Kit (Qiagen, Basel, Switzerland) 
according the manufactors protocol. For standard curves, the peripheral venous blood was 
taken from a volunteer to extract genomic DNA (the platelet enriched plasma was removed) 
to amplify genes of interest. After amplification DNA templates were purified with the 
Qiagen QIAquick PCR Purification Kit (Qiagen, Basel, Switzerland) and the absorption at 
260nm was measured to determine the gene copy number and produce serial standard 
dilutions. 
Primers for the RT Q-PCR analysis of mitochondrial DNA (mtDNA)-tRNAleu [48] are 
mtF3212 (5`CACCAAGAACAGGGTTTGT3`) and mtR3319 (5`TGGCCATGGGTATGTT 
GTTAA3`) [49], those for nuclear DNA (nDNA), human polymerase γ accessory subunit 
gene (ASPOLG) are ASPG3F 5`GAGCTGTTGACGGAAAGGAG3` and ASPG4R (5`CAG 
AAGAGAATCCCGGCTAAG3`) [50]. For each DNA extract, the nDNA and mtDNA gene 
respectively were quantified separately in triplicates and/or duplicates by real-time 
quantitative PCR in the presence of SYBR-green with the use of the Applied Biosystems 
StepOneTM cycler (Applied-Biosystems). PCR reactions contained 1x Power SYBR Green 
Master Mix (ABI P/N 4367659, Rotkreuz, Switzerland), 1µM of each primer and 1ng of 
DNA extract. The PCR amplification consisted of a single denaturation-enzyme-activation 
step of 10min at 95°C, followed by 40 cycles of 15sec denaturation at 95°C and 60sec of 
annealing / extension at 60°C. Fluorescence was measured at the end of each extension step. 
A standard curve of corresponding mtDNA and nDNA template equivalents with defined 
copy numbers were included in each run to quantify the content of mtDNA and nDNA in each 
sample. Data thus obtained were analyzed by using the cycle threshold (CT) of each 
amplification reaction relating it to its respective standard curve. Results from the quantitative 
PCR were expressed as the ratio of the mean mitochondrial DNA to the mean nuclear DNA 
content.   
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Statistical Analysis. Data were presented as mean ± S.E.M. For statistical comparisons, 
unpaired Student’s t-test or Two-way ANOVA was used. P values less than 0.05 were 
considered statistically significant. 
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5. Conclusion 
Reduced energy metabolism together with mitochondrial failure and oxidative stress 
has been recognized as prominent and early events in AD. However, the pathogenic 
mechanisms underlying these defects are far to be resolved. The aim of the present thesis was 
to gain new insights into the contribution of the two unquestionable AD-related proteins, Aβ 
and tau, on one hand, and the mode of action of GBE on the other hand, toward mitochondrial 
modulation. 
 
Combining transgenesis[3-5], quantitative proteomics and functional assays, our 
findings support first of all that Aβ and tau acting synergistically heighten mitochondrial 
respiration deficits. Thereby, hyperphosphorylated tau may drive a vicious cycle within the 
Aβ cascade. We found also that age-related oxidative stress may exaggerate the dysfunctional 
energy homeostasis and in turn, take part in the vicious cycle finally leading to cell death 
(Figure 11). Our results are in line with recent studies associating Aβ and tau with oxidative 
stress[6-9] as well as axonal traffic inhibition, synapse starvation and neurodegeneration[7, 10]. A 
crucial role for mitochondria in AD is further underpinned by findings linking maternal 
inheritance of mtDNA to both AD predisposition and glucose hypometabolism[11] that may 
reflect energy disturbances as found, e.g., in our tripleAD model.  
 
In line with the recent “intracellular hypothesis”[12-15], soluble oligomers appear to 
interfere with hippocampal synaptic function and memory[16]. Interestingly, in this new 
paradigm, mitochondria sound as key features in the pathological mechanisms leading to 
synaptic failure and cell loss. Our group reported a direct impact of Aβ oligomeric on ∆ψ and 
ATP levels in APP transgenic mice model[17]. We also showed first evidence for an increased 
vulnerability of P301L tau mitochondria towards oligomers Aβ insult in vitro[18]. These 
findings were confirmed in our tripleAD study demonstrating an interplay between Aβ and tau 
at the mitochondrial level in vivo. In the second part of the thesis, we ripened our 
understanding of the specific actions of soluble Aβ on mitochondrial respiration. For this 
approach, a novel high-resolution respiratory protocol was established and an APP cell model 
mimicing relevant conditions of AD patients by secreting Aβ within a picomolar range was 
used. We observed that Aβ oligomers caused serious impairments of the total cellular 
respiration with main impacts on complexes III, IV and V.  
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The crucial role of mitochondrial dysfunction in the biochemical pathways by which 
Aβ can lead to neuronal dysfunction in AD[17, 18] is particularly challenging in order to 
establish therapeutic treatments. To test this idea we investigated the potential effect of a 
natural antioxidant, GBE, on Aβ-induced mitochondrial deficits. Although the precise 
molecular mechanisms inside cells as well as on mitochondria stay unknown yet, the findings 
of the thesis and the findings of others[19-23] indicate substantial mitochondria modulating 
properties of GBE. We could clearly show that GBE improved OXPHOS performance and 
was able to restore Aβ-induced mitochondria failure. Hereby, the increase in mitochondrial 
content might represent an important early event. Thus, we observed an up-regulation of 
mtDNA in cells treated with GBE, but at the same time, a decrease of mitochondria mass in 
GBE-treated cells suggesting that GBE may act not only at a functional level but also at a 
genetic one[24-26]. Although further studies are necessary, we can speculate that a GBE 
treatment may not only enhance mtDNA but may modulate mitochondria biogenesis after 
chronic exposure. Taking into account the increasing interest in mitochondrial stabilization as 
intervention strategy in AD, the regulating mechanisms of GBE on mitochondria function 
suggested by this study qualifies this drug as a therapeutic candidate. 
 
In total, our results strengthen the key role of mitochondria in the pathogenesis of AD 
demonstrating close relationship with the two indisputable hallmarks of the disease acting 
independently as well as synergistically on the vital organelle. Consequently, besides the 
treatment and/or removal of both Aβ and tau pathology, strategies involving efforts to protect 
cells at the mitochondrial level by stabilizing or restoring mitochondrial function or to 
interfere with the energy metabolism appear to be promising in order to prevent AD. 
Moreover, the better understanding of the biochemical pathways by which mitochondria-
protecting substances such as GBE act may not only optimize our therapeutic options but also 
clarify the role of mitochondria in the pathogenesis of AD (Figure 11). Our age-related Aβ 
and tau transgenic mouse model (tripleAD) may be very valuable in order to monitor 
therapeutic interventions at the mitochondrial level and the impact to prevent the progression 
of Aβ deposits and tau hyperphosphorylation at early stages of the disease.  
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Figure 12. A hypothetical sequence of the pathogenic steps linking amyloid-beta peptide (Aβ) and tau 
pathologies with mitochondrial dysfunction as well as early use of Ginkgo biloba extract (GBE). Aβ and 
tau may act synergistically on mitochondria inducing strong failure in mitochondrial respiration und function 
thereby triggering a vicious cycle. In addition, defects in energy metabolism may increase BACE1 activity[1] 
which, in turn, increases the production of Aβ. Thus, a comprehensive vision of the neuropathophysiologic 
mechanisms that result in AD reveals several vicious cycles within a larger vicious cycle. All of them, once set 
in motion, amplify their own processes, thus accelerating the development of AD. GBE used at early stage of 
the disease could be promising for AD prevention and treatment (adapted from Rhein and Eckert, 2007[2]). 
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Abbreviations  
Aβ  Amyloid-beta peptide 
ABAD  Aβ binding protein alcohol dehydrogenase 
AD  Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase  
A2M  Alpha-2-macroglobulin 
AICD  Aβ intracellular cytoplasmic domain 
AIF  Apoptosis-inducing factor 
APH1  Anterior pharynx-defective 1 
APOE  Apolipoprotein E 
APP  Amyloid precursor protein 
CAA  Cerebral amyloid angiopathy 
CaMKII Calcium-calmodulin dependent protein kinase II 
CAT  Catalase 
cdk5  Cyclin-dependent kinase 5 
C83  83-amino-acid Ct APP fragment 
C99  99-amino-acid Ct APP fragment 
COX  Cytochrome c oxidase 
Ct  Carboxy-terminal 
Cu/Zn SOD Copper/zinc superoxide dismutase 
∆ψ   Mitochondrial membrane potential 
ERK2  Extracellular signal-regulated kinase 2 
ETC  Electron transport chain 
FAD  Familial Alzheimer’s disease form 
FADH2 Flavin adenine dinucleotide 
4R  Four microtubule binding repeats 
FTDP-17 Fronto-temporal dementia with Parkinsonism linked to chromosome 17 
GAB2  Growth factor receptor-bound protein associated binding-protein 2 
GBE  Ginkgo biloba extract 
GPX  Glutathione peroxidase 
GSH  Glutathione 
GSK-3β Glycogen synthase kinase-3β 
H2O2  Hydrogen peroxide  
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HNE  4-hydroxynonenal 
IDE  Insulin-degrading enzyme 
IMM  Inner mitochondrial membrane 
IMS  Intermembrane space 
iTRAQ  Isobaric tags for relative and absolute quantitation 
LRP  Low-density lipid receptor-related protein 
LTP  Long-term potentiation 
MAOA  Monoamine oxidase A 
MAOB Monoamine oxidase B 
MAP1  Microtubule-associated protein 1  
MAP2  Microtubule-associated protein 2 
MARK Mitogen-associated protein affinity-regulating kinases 
MCI   Mild cognitive impairment  
MDA  Malondialdehyde 
MMP  Mitochondrial membrane permeabilization 
MnSOD Manganese superoxide dismutase 
mtDNA Mitochondrial DNA 
mtNOS Mitochondrial nitric oxide synthase 
NADH Nicotine adenine dinucleotide 
nDNA  Nuclear DNA 
NFTs  Neurofibrillay tangles 
NMDA  N-methyl-D-aspartate  
NO.  Nitric oxide 
NOS  Nitric oxide synthase 
Nt  Amino-terminal 
O2-.  Superoxide anion 
OH.  Hydroxyl radical  
OMM  Outer mitochondrial membrane 
ONOO- Peroxynitrite 
OXPHOS Oxidative phosphorylation system 
PAF  Platelet activating factor 
PDGF  Platelet-derived growth factor 
PEN-2  Presenilin enhancer 2 
PET  Positron emission tomography 
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PHFs  Paired helical filaments 
pR5  P301L mutant tau transgenic pR5 mice 
PSEN1 Presenelin 1  
PSEN2 Presenelin 2 
RNS  Reactive nitrogen species 
ROS  Reactive oxygen species 
SAD  Sporadic Alzheimer’s disease form 
TCA  Tricarboxylic acid cycle 
TM  Transmembrane 
3R  Three microtubule binding repeats  
TOM  Translocator outer membrane 
tripleAD  mutated Tau (P301L), PS2 (N141l) and APPSwe (KM670/671NL) triple 
transgenic mouse model 
UCPs  Uncoupling proteins 
VDAC  Voltage-dependant anion channels 
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